Hereditary neurological disease
MONDO:0100545A heterogeneous group of genetic conditions with Mendelian (autosomal dominant, recessive, or X-linked) or chromosomal etiology characterized by abnormalities in the brain, spinal cord, nerves, or muscles.
Also known as: neurogenetic disease
5772 clinical trials for this condition and its sub-types, 6 tagged with Hereditary neurological disease itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Hereditary neurological disease
-
Parkinson disease 1,165 trials · 1,292 incl. sub-types
6 sub-types
- Late-onset Parkinson disease 3 trials · 143 incl. sub-types Sub-types →
- Young-onset Parkinson disease 9 trials · 11 incl. sub-types Sub-types →
- Parkinson disease 16 0 trials
- Parkinson disease 25, autosomal recessive early-onset, with impaired intellectual development 0 trials
- Parkinson disease, mitochondrial 0 trials
- Parkinsonian-pyramidal syndrome 0 trials Sub-types →
-
Anxiety 1,030 trials
-
Hereditary neuromuscular disease 3 trials · 932 incl. sub-types
22 sub-types
- Hereditary peripheral neuropathy 6 trials · 478 incl. sub-types Sub-types →
- Muscular dystrophy 74 trials · 288 incl. sub-types Sub-types →
- Hereditary motor neuron disease 1 trial · 169 incl. sub-types Sub-types →
- Hereditary spastic paraplegia 27 trials · 33 incl. sub-types Sub-types →
- Benign paroxysmal positional vertigo 18 trials
- Meniere disease 16 trials Sub-types →
- RYR1-related myopathy 5 trials · 6 incl. sub-types Sub-types →
- Congenital myasthenic syndrome 5 trials Sub-types →
- Malignant hyperthermia of anesthesia 5 trials
- SCN4A-related channelopathy 1 trial · 2 incl. sub-types Sub-types →
- Early-onset myopathy with fatal cardiomyopathy 1 trial
- Andersen-Tawil syndrome 0 trials
- CNGB3-related retinopathy 0 trials Sub-types →
- KY-related neuromyopathy 0 trials Sub-types →
- Morimoto-Ryu-Malicdan neuromuscular syndrome 0 trials
- X-linked recessive mitochondrial myopathy 0 trials
- Myofibrillar myopathy 1 0 trials
- Myotonia congenita, autosomal dominant 0 trials
- Myotonia congenita, autosomal recessive 0 trials
- Neuromuscular disorder, congenital, with dysmorphic facies 0 trials
- Periodic paralysis with later-onset distal motor neuropathy 0 trials
- Vertigo, benign recurrent, 1 0 trials
-
Inherited neurodegenerative disorder 10 trials · 807 incl. sub-types
82 sub-types
- Frontotemporal dementia 132 trials · 178 incl. sub-types Sub-types →
- Hereditary motor neuron disease 1 trial · 169 incl. sub-types Sub-types →
- Hereditary cerebellar ataxia 0 trials · 116 incl. sub-types Sub-types →
- Huntington disease and related disorders 0 trials · 91 incl. sub-types Sub-types →
- Progressive supranuclear palsy 73 trials · 77 incl. sub-types Sub-types →
- Leukodystrophy 6 trials · 72 incl. sub-types Sub-types →
- Familial Alzheimer disease 13 trials · 55 incl. sub-types Sub-types →
- Hereditary spastic paraplegia 27 trials · 33 incl. sub-types Sub-types →
- Hereditary optic atrophy 6 trials · 23 incl. sub-types Sub-types →
- Neuronal ceroid lipofuscinosis 6 trials · 23 incl. sub-types Sub-types →
- GM2 gangliosidosis 14 trials · 19 incl. sub-types Sub-types →
- Kennedy disease 19 trials
- Corticobasal syndrome 19 trials
- Frontotemporal dementia with motor neuron disease 13 trials · 19 incl. sub-types Sub-types →
- Posterior cortical atrophy 11 trials
- Chediak-Higashi syndrome 9 trials
- Neurodegeneration with brain iron accumulation 1 trial · 8 incl. sub-types Sub-types →
- APP-related brain and vascular amyloidosis 0 trials · 5 incl. sub-types Sub-types →
- Frontotemporal dementia and/or amyotrophic lateral sclerosis 0 trials · 5 incl. sub-types Sub-types →
- Inherited Creutzfeldt-Jakob disease 5 trials
- TUBB4A-related neurologic disorder 4 trials Sub-types →
- Fatal familial insomnia 4 trials
- Mitochondrial DNA depletion syndrome 4a 3 trials
- Alzheimer disease 17 1 trial
- Alzheimer disease 18 1 trial
- Ataxia-telangiectasia-like disorder 1 trial Sub-types →
- Developmental and epileptic encephalopathy, 35 1 trial
- Neurodegeneration, childhood-onset, stress-induced, with variable ataxia and seizures 1 trial
- Neurodegenerative syndrome due to cerebral folate transport deficiency 1 trial
- Neuronal intranuclear inclusion disease 1 trial
- Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome 1 trial
- DCTN1-related neurodegeneration 0 trials Sub-types →
- Huntington disease-like 1 0 trials
- Huntington disease-like 2 0 trials
- ITM2B amyloidosis 0 trials Sub-types →
- PEHO syndrome 0 trials
- PRKAR1B-related neurodegenerative dementia with intermediate filaments 0 trials
- X-linked neurodegenerative syndrome, Bertini type 0 trials
- X-linked neurodegenerative syndrome, Hamel type 0 trials
- Agenesis of the corpus callosum with peripheral neuropathy 0 trials
- Amyotrophic lateral sclerosis-parkinsonism-dementia complex 0 trials
- Angioid streaks of choroid 0 trials
- Attenuated Chédiak-Higashi syndrome 0 trials
- Autosomal recessive cerebral atrophy 0 trials
- Boylan dew greco syndrome 0 trials
- Cerebellar ataxia-hypogonadism syndrome 0 trials Sub-types →
- Cerebral sclerosis similar to Pelizaeus-Merzbacher disease 0 trials
- Combined oxidative phosphorylation deficiency 29 0 trials
- Deafness dystonia syndrome 0 trials
- Diffuse cerebral and cerebellar atrophy - intractable seizures - progressive microcephaly syndrome 0 trials
- Dystonia, childhood-onset, with optic atrophy and basal ganglia abnormalities 0 trials
- Early-childhood-onset neurodegeneration with retinitis pigmentosa, sensorineural hearing loss, and demyelinating peripheral neuropathy 0 trials
- Early-onset progressive diffuse brain atrophy-microcephaly-muscle weakness-optic atrophy syndrome 0 trials
- Encephalopathy due to beta-mercaptolactate-cysteine disulfiduria 0 trials
- Encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy 0 trials Sub-types →
- Facial onset sensory and motor neuronopathy 0 trials
- Fatal post-viral neurodegenerative disorder 0 trials
- Ferro-cerebro-cutaneous syndrome 0 trials
- Hereditary sensory neuropathy-deafness-dementia syndrome 0 trials
- Hypotonia, infantile, with psychomotor retardation and characteristic facies 0 trials Sub-types →
- Infantile cerebellar-retinal degeneration 0 trials
- Infantile-onset axonal motor and sensory neuropathy-optic atrophy-neurodegenerative syndrome 0 trials
- Microphthalmia-brain atrophy syndrome 0 trials
- Myoclonic cerebellar dyssynergia 0 trials
- Neurodegeneration and seizures due to copper transport defect 0 trials
- Neurodegeneration with ataxia and late-onset optic atrophy 0 trials
- Neurodegeneration with ataxia, dystonia, and gaze palsy, childhood-onset 0 trials
- Neurodegeneration with developmental delay, early respiratory failure, myoclonic seizures, and brain abnormalities 0 trials
- Neurodegeneration, childhood-onset, with ataxia, tremor, optic atrophy, and cognitive decline 0 trials
- Neurodegeneration, childhood-onset, with cerebellar ataxia and cognitive decline 0 trials
- Neurodegeneration, childhood-onset, with cerebellar atrophy 0 trials
- Neurodegeneration, childhood-onset, with hypotonia, respiratory insufficiency, and brain imaging abnormalities 0 trials
- Neurodegeneration, childhood-onset, with multisystem involvement due to mitochondrial dysfunction 0 trials
- Neurodegeneration, childhood-onset, with progressive microcephaly 0 trials
- Neurodegeneration, early-onset, with choreoathetoid movements and microcytic anemia 0 trials
- Neurodegeneration, infantile-onset, biotin-responsive 0 trials
- Neurodegenerative disorder with cerebellar and caudate atrophy 0 trials
- Neurodegenerative disorder, X-linked, female-restricted, with parkinsonism and cognitive impairment 0 trials
- Psychomotor regression-oculomotor apraxia-movement disorder-nephropathy syndrome 0 trials
- Radiation sensitivity/chromosome instability syndrome, autosomal dominant 0 trials
- Severe neurodegenerative syndrome with lipodystrophy 0 trials
- Striatonigral degeneration 0 trials Sub-types →
-
Inherited retinal dystrophy 41 trials · 510 incl. sub-types
105 sub-types
- Age-related macular degeneration 190 trials · 334 incl. sub-types Sub-types →
- Retinitis pigmentosa 84 trials · 89 incl. sub-types Sub-types →
- Hereditary macular dystrophy 3 trials · 70 incl. sub-types Sub-types →
- Cone-rod dystrophy 17 trials · 21 incl. sub-types Sub-types →
- Leber congenital amaurosis 10 trials · 12 incl. sub-types Sub-types →
- ABCA4-related retinopathy 7 trials · 11 incl. sub-types Sub-types →
- BEST1-related dominant retinopathy 1 trial · 7 incl. sub-types Sub-types →
- RHO-related retinopathy 0 trials · 7 incl. sub-types Sub-types →
- RPE65-related recessive retinopathy 5 trials · 7 incl. sub-types Sub-types →
- RPGR-related retinopathy 0 trials · 7 incl. sub-types Sub-types →
- Choroideremia 6 trials Sub-types →
- PRPF31-related retinopathy 1 trial · 4 incl. sub-types Sub-types →
- X-linked retinoschisis 4 trials
- Ornithine aminotransferase deficiency 4 trials
- ELOVL4-related maculopathy 0 trials · 3 incl. sub-types Sub-types →
- RLBP1-related retinopathy 2 trials · 3 incl. sub-types Sub-types →
- Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations 3 trials
- BEST1-related recessive retinopathy 0 trials · 2 incl. sub-types Sub-types →
- EYS-related retinopathy 1 trial · 2 incl. sub-types Sub-types →
- LCA5-related retinopathy 1 trial · 2 incl. sub-types Sub-types →
- PRPH2-related retinopathy 1 trial · 2 incl. sub-types Sub-types →
- Revesz syndrome 2 trials
- Late-onset retinal degeneration 2 trials
- AIPL1-related retinopathy 1 trial Sub-types →
- ATF6-related retinopathy 0 trials · 1 incl. sub-types Sub-types →
- CNGB1-related retinopathy 0 trials · 1 incl. sub-types Sub-types →
- FLVCR1-related retinopathy with or without ataxia 0 trials · 1 incl. sub-types Sub-types →
- GUCY2D retinopathy 0 trials · 1 incl. sub-types Sub-types →
- RDH5-related retinopathy 0 trials · 1 incl. sub-types Sub-types →
- Retinoschisis of fovea 1 trial
- ADAM9-related retinopathy 0 trials Sub-types →
- CACNA1F-related retinopathy 0 trials Sub-types →
- CACNA2D4-related retinopathy 0 trials Sub-types →
- CDHR1-related retinopathy 0 trials Sub-types →
- CERKL-related retinopathy 0 trials Sub-types →
- CNGA1-related retinopathy 0 trials Sub-types →
- CNGA3-related retinopathy 0 trials Sub-types →
- CRX-related retinopathy 0 trials Sub-types →
- GNAT2-related retinopathy 0 trials Sub-types →
- GPR179-related retinopathy 0 trials Sub-types →
- GRM6-related retinopathy 0 trials Sub-types →
- GUCA1A-related retinopathy 0 trials Sub-types →
- HGSNAT-related retinopathy 0 trials Sub-types →
- IDH3B-related retinopathy 0 trials Sub-types →
- IMPDH1-related retinopathy 0 trials Sub-types →
- IMPG1-related dominant retinopathy 0 trials Sub-types →
- IMPG1-related recessive retinopathy 0 trials Sub-types →
- IMPG2-related dominant retinopathy 0 trials Sub-types →
- IMPG2-related recessive retinopathy 0 trials Sub-types →
- KCNV2-related retinopathy 0 trials Sub-types →
- KIZ-related retinopathy 0 trials Sub-types →
- LRIT3-related retinopathy 0 trials Sub-types →
- MAK-related retinopathy 0 trials Sub-types →
- MERTK-related retinopathy 0 trials Sub-types →
- MRCS syndrome 0 trials
- NMNAT1-related retinopathy 0 trials Sub-types →
- NYX-related retinopathy 0 trials Sub-types →
- Oguchi disease 0 trials Sub-types →
- PCARE-related retinopathy 0 trials Sub-types →
- PDE6A-related retinopathy 0 trials Sub-types →
- PDE6C-related retinopathy 0 trials Sub-types →
- PDE6G-related retinopathy 0 trials Sub-types →
- PROM1-related retinopathy 0 trials Sub-types →
- PRPF8-related retinopathy 0 trials Sub-types →
- RAB28-related retinopathy 0 trials Sub-types →
- RD3-related retinopathy 0 trials Sub-types →
- RDH12-related dominant retinopathy 0 trials
- RDH12-related recessive retinopathy 0 trials Sub-types →
- REEP6-related retinopathy 0 trials Sub-types →
- RP1-related dominant retinopathy 0 trials
- RP1-related recessive retinopathy 0 trials
- RP2-related retinopathy 0 trials Sub-types →
- RPE65-related dominant retinopathy 0 trials Sub-types →
- SNRNP200-related dominant retinopathy 0 trials Sub-types →
- SPATA7-related retinopathy 0 trials Sub-types →
- Sorsby fundus dystrophy 0 trials Sub-types →
- TOPORS-related retinopathy 0 trials Sub-types →
- TRPM1-related retinopathy 0 trials Sub-types →
- TTLL5-related retinopathy 0 trials Sub-types →
- X-linked intellectual disability-limb spasticity-retinal dystrophy-diabetes insipidus syndrome 0 trials
- X-linked retinal dysplasia 0 trials
- Aceruloplasminemia 0 trials
- Amaurosis-hypertrichosis syndrome 0 trials
- Choroideremia-deafness-obesity syndrome 0 trials
- Dystrophies primarily involving the retinal pigment epithelium 0 trials
- Ectopia lentis-chorioretinal dystrophy-myopia syndrome 0 trials
- Familial benign flecked retina 0 trials
- Foveal hypoplasia-presenile cataract syndrome 0 trials
- Helicoid peripapillary chorioretinal degeneration 0 trials
- Infantile cerebellar-retinal degeneration 0 trials
- Macular degeneration, early-onset 0 trials
- Microcephaly and chorioretinopathy 1 0 trials
- Microcephaly with or without chorioretinopathy, lymphedema, or intellectual disability 0 trials
- Microcornea-myopic chorioretinal atrophy 0 trials
- Oligocone trichromacy 0 trials
- Pigmented paravenous retinochoroidal atrophy 0 trials
- Progressive bifocal chorioretinal atrophy 0 trials
- Progressive retinal dystrophy due to retinol transport defect 0 trials
- Retinal degeneration-nanophthalmos-glaucoma syndrome 0 trials
- Retinal dystrophies primarily involving Bruch's membrane 0 trials Sub-types →
- Retinal dystrophy in systemic or cerebroretinal lipidoses 0 trials
- Retinal dystrophy with inner retinal dysfunction and ganglion cell anomalies 0 trials
- Retinal dystrophy, X-linked, Gardner-Hardcastle type 0 trials
- Retinoschisis, autosomal dominant 0 trials
- Vitreoretinal dystrophy 0 trials
-
Mendelian neurodevelopmental disorder 0 trials · 207 incl. sub-types
275 sub-types
- Genetic developmental and epileptic encephalopathy 2 trials · 83 incl. sub-types Sub-types →
- Prader-Willi syndrome 31 trials Sub-types →
- Rett syndrome 31 trials
- Intellectual disability, autosomal dominant 0 trials · 23 incl. sub-types Sub-types →
- X-linked intellectual disability 1 trial · 15 incl. sub-types Sub-types →
- CACNA1A-related complex neurodevelopmental disorder 1 trial · 9 incl. sub-types Sub-types →
- Autosomal recessive primary microcephaly 0 trials · 8 incl. sub-types Sub-types →
- Smith-Magenis syndrome 5 trials
- Rubinstein-Taybi syndrome 3 trials Sub-types →
- Alternating hemiplegia of childhood 3 trials Sub-types →
- FOXG1 disorder 2 trials
- GRIN-related complex neurodevelopmental disorder 2 trials Sub-types →
- Neurodevelopmental disorder with involuntary movements 2 trials
- CAMK2D-related neurodevelopmental disorder and dilated cardiomyopathy 1 trial
- Dyneinopathy 0 trials · 1 incl. sub-types Sub-types →
- Intellectual disability, autosomal recessive 0 trials · 1 incl. sub-types Sub-types →
- Microcephalic osteodysplastic primordial dwarfism type I 1 trial
- Microcephalic osteodysplastic primordial dwarfism type II 1 trial
- Neurodevelopmental disorder with cerebellar atrophy and motor dysfunction 1 trial
- Neurodevelopmental disorder with or without variable brain abnormalities; NEDBA 1 trial
- Orofaciodigital syndrome I 1 trial
- AFG2B-related complex neurodevelopmental disorder with motor features and hearing loss 0 trials
- AHDC1-related intellectual disability - obstructive sleep apnea - mild dysmorphism syndrome 0 trials
- ARF3-related neurodevelopmental disorder 0 trials
- ATXN7L3-related developmental delay, hypotonia and facial dysmorphism 0 trials
- Alzahrani-Kuwahara syndrome 0 trials
- Amish lethal microcephaly 0 trials
- Au-Kline syndrome 0 trials
- Brunet-Wagner neurodevelopmental syndrome 0 trials
- CBX1-related neurodevelopmental disorder 0 trials
- CK syndrome 0 trials
- CNOT9-related developmental disorder with seizures 0 trials
- CTR9-related neurodevelopmental disorder 0 trials
- Chilton-Okur-Chung neurodevelopmental syndrome 0 trials
- DDX17-related neurodevelopmental disorder 0 trials
- DEAF1-associated neurodevelopmental disorder 0 trials Sub-types →
- DIP2C-related developmental disorder with speech delay 0 trials
- Delpire-McNeill syndrome 0 trials
- Dentici-Novelli neurodevelopmental syndrome 0 trials
- Dursun-Ozgul neurodevelopmental syndrome 0 trials
- Dworschak-Punetha neurodevelopmental syndrome 0 trials
- EPB41L3-related developmental disorder with delayed myelination and seizures 0 trials
- El Hayek-Chahrour neurodevelopmental disorder 0 trials
- FAT4-related neurodevelopmental disorder 0 trials
- FEZF2-related neurodevelopmental disorder 0 trials
- Ferguson-Bonni neurodevelopmental syndrome 0 trials
- GABRA4-related neurodevelopmental disorder with seizures 0 trials
- GABRD-related neurodevelopmental disorder with epilepsy 0 trials
- HDAC3-related neurodevelopmental disorder 0 trials
- HMGB1-related brachyphalangy, polydactyly and tibial aplasia syndrome 0 trials
- HNRNPC-related neurodevelopmental disorder 0 trials Sub-types →
- Hao-Fountain syndrome due to USP7 mutation 0 trials
- Harel-Tora neurodevelopmental syndrome 0 trials
- Harel-Yoon syndrome 0 trials
- Hiatt-Neu-Cooper neurodevelopmental syndrome 0 trials
- Houge-Janssens syndrome 3 0 trials
- Jeffries-Lakhani neurodevelopmental syndrome 0 trials
- KCND2-related neurodevelopmental disorder with or without seizures 0 trials
- KCNH1 associated disorder 0 trials Sub-types →
- KCNK3-related developmental delay with sleep apnea 0 trials
- KDM2B-related neurodevelopmental disorder 0 trials
- Karayol-Borroto-Haghshenas neurodevelopmental syndrome 0 trials
- Kariminejad neurodevelopmental syndrome 0 trials
- Li-Takada-Miyake syndrome 0 trials
- MYCBP2-related developmental delay with corpus callosum defects 0 trials
- MYH10-related neurodevelopmental disorder with congenital anomalies 0 trials
- Marbach-Schaaf neurodevelopmental syndrome 0 trials
- NACC1-related neurodevelopmental disorder with epilepsy, cataracts and episodic irritability 0 trials
- Nil-Deshwar neurodevelopmental syndrome 0 trials
- Okur-Chung neurodevelopmental syndrome 0 trials
- PAX5-related B lymphopenia and autism spectrum disorder 0 trials
- PIP5K1C-related neurodevelopmental disorder 0 trials
- PPFIA3-related neurodevelopmental disorder 0 trials
- PPP2R1A-related intellectual disability 0 trials
- PRPF19-related neurodevelopmental disorder 0 trials
- Pitt-Hopkins-like syndrome 2 0 trials
- Poirier-Bienvenu neurodevelopmental syndrome 0 trials
- Popov-Chang syndrome 0 trials
- RFX3-related neurodevelopmental disorder with autism and other behavioural abnormalities 0 trials
- RFX4-related neurodevelopmental disorder with autism and other behavioural abnormalities 0 trials
- RNU5B-1 related neurodevelopmental disorder with seizures and joint laxity 0 trials
- Ramond-Elliott neurodevelopmental syndrome 0 trials
- SETD2-related neurodevelopmental disorder without or with macrocephaly/overgrowth 0 trials Sub-types →
- SOX11-related complex neurodevelopmental disorder with or without congenital anomalies 0 trials
- SYNCRIP-related neurodevelopmental disorder 0 trials
- Stankiewicz-Isidor syndrome 0 trials
- TRA2B-related neurodevelopmental disorder 0 trials
- WDR5-related neurodevelopmental disorder 0 trials
- Wieacker-Wolff syndrome 0 trials
- X-linked complex neurodevelopmental disorder 0 trials Sub-types →
- Aplasia cutis-enamel dysplasia syndrome 0 trials
- Autosomal dominant primary microcephaly 0 trials Sub-types →
- Cerebellar atrophy, visual impairment, and psychomotor retardation; 0 trials
- Cerebral palsy, spastic quadriplegic, 2 0 trials
- Cerebral palsy, spastic quadriplegic, 3 0 trials
- Complex cortical dysplasia with other brain malformations 5 0 trials
- Developmental delay and seizures with or without movement abnormalities 0 trials
- Developmental delay with autism spectrum disorder and gait instability 0 trials
- Developmental delay with variable intellectual impairment and behavioral abnormalities 0 trials
- Encephalopathy, neonatal severe, with lactic acidosis and brain abnormalities 0 trials
- Intellectual developmental disorder and retinitis pigmentosa; IDDRP 0 trials
- Intellectual developmental disorder with polymicrogyria and seizures 0 trials
- Intellectual disability, autosomal dominant 29 0 trials
- Microcephalic osteodysplastic primordial dwarfism, type 3 0 trials
- Microcephaly and chorioretinopathy 0 trials Sub-types →
- Microcephaly with lissencephaly and/or hydranencephaly 0 trials Sub-types →
- Microcephaly with or without chorioretinopathy, lymphedema, or intellectual disability 0 trials
- Microcephaly, progressive, with simplified gyral pattern and cerebellar hypoplasia 0 trials
- Neurocardiorenal malformation syndrome 0 trials
- Neurodevelopmental disorder and structural brain anomalies with or without seizures and spasticity 0 trials
- Neurodevelopmental disorder plus optic atrophy 0 trials
- Neurodevelopmental disorder with absent language and variable seizures 0 trials
- Neurodevelopmental disorder with absent speech and movement and behavioral abnormalities 0 trials
- Neurodevelopmental disorder with achalasia, polyneuropathy, and alacrima 0 trials
- Neurodevelopmental disorder with alopecia and brain abnormalities 0 trials
- Neurodevelopmental disorder with ataxia and brain abnormalities 0 trials
- Neurodevelopmental disorder with ataxia, hypotonia, and microcephaly 0 trials
- Neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter 0 trials
- Neurodevelopmental disorder with behavioral abnormalities and childhood-onset spastic paraplegia 0 trials
- Neurodevelopmental disorder with behavioral abnormalities, absent speech, and hypotonia 0 trials
- Neurodevelopmental disorder with behavioral, ear, and skeletal abnormalities 0 trials
- Neurodevelopmental disorder with brain anomalies and with or without vertebral or cardiac anomalies 0 trials
- Neurodevelopmental disorder with cardiomyopathy, spasticity, and brain abnormalities 0 trials
- Neurodevelopmental disorder with cataracts, poor growth, and dysmorphic facies 0 trials
- Neurodevelopmental disorder with central and peripheral motor dysfunction 0 trials
- Neurodevelopmental disorder with central hypotonia and dysmorphic facies 0 trials Sub-types →
- Neurodevelopmental disorder with cerebellar atrophy and with or without seizures 0 trials
- Neurodevelopmental disorder with cerebellar hypoplasia and spasticity 0 trials
- Neurodevelopmental disorder with cerebral atrophy and variable facial dysmorphism 0 trials
- Neurodevelopmental disorder with characteristic facial and ectodermal features and tetraparesis 1 0 trials
- Neurodevelopmental disorder with coarse facies and mild distal skeletal abnormalities 0 trials
- Neurodevelopmental disorder with congenital cardiac defects and variable renal and ocular abnormalities 0 trials
- Neurodevelopmental disorder with craniofacial dysmorphism and skeletal defects 0 trials
- Neurodevelopmental disorder with dysmorphic facies and behavioral abnormalities 0 trials
- Neurodevelopmental disorder with dysmorphic facies and cerebellar hypoplasia 0 trials
- Neurodevelopmental disorder with dysmorphic facies and distal limb anomalies 0 trials
- Neurodevelopmental disorder with dysmorphic facies and distal skeletal anomalies 0 trials
- Neurodevelopmental disorder with dysmorphic facies and ischiopubic hypoplasia 0 trials
- Neurodevelopmental disorder with dysmorphic facies and skeletal and brain abnormalities 0 trials
- Neurodevelopmental disorder with dysmorphic facies and thin corpus callosum 0 trials
- Neurodevelopmental disorder with dysmorphic facies and variable seizures 0 trials
- Neurodevelopmental disorder with dysmorphic facies, absent speech and ambulation, and brain abnormalities 0 trials
- Neurodevelopmental disorder with dysmorphic facies, brain anomalies, and seizures 0 trials
- Neurodevelopmental disorder with dysmorphic facies, impaired speech, and hypotonia 0 trials
- Neurodevelopmental disorder with dysmorphic facies, sleep disturbance, and brain abnormalities 0 trials
- Neurodevelopmental disorder with dystonia and seizures 0 trials
- Neurodevelopmental disorder with early-onset parkinsonism and behavioral abnormalities 0 trials
- Neurodevelopmental disorder with early-onset seizures, facial dysmorphism, and behavioral abnormalities 0 trials
- Neurodevelopmental disorder with epilepsy and brain atrophy 0 trials
- Neurodevelopmental disorder with epilepsy and hypoplasia of the corpus callosum 0 trials
- Neurodevelopmental disorder with epilepsy, cataracts, feeding difficulties, and delayed brain myelination 0 trials
- Neurodevelopmental disorder with epilepsy, spasticity, and brain atrophy 0 trials
- Neurodevelopmental disorder with eye movement abnormalities and ataxia 0 trials
- Neurodevelopmental disorder with facial dysmorphism, absent language, and pseudo-pelger-huet anomaly 0 trials
- Neurodevelopmental disorder with gait disturbance, dysmorphic facies, and behavioral abnormalities, X-linked 0 trials
- Neurodevelopmental disorder with growth impairment, quadriparesis, and poor or absent speech 0 trials
- Neurodevelopmental disorder with growth retardation, dysmorphic facies, and corpus callosum abnormalities 0 trials
- Neurodevelopmental disorder with hearing loss and spasticity 0 trials
- Neurodevelopmental disorder with hyperkinetic movements and dyskinesia 0 trials
- Neurodevelopmental disorder with hyperkinetic movements, seizures, and structural brain abnormalities 0 trials
- Neurodevelopmental disorder with hypotonia and autistic features with or without hyperkinetic movements 0 trials
- Neurodevelopmental disorder with hypotonia and brain abnormalities 0 trials
- Neurodevelopmental disorder with hypotonia and cerebellar atrophy, with or without seizures 0 trials
- Neurodevelopmental disorder with hypotonia and characteristic brain abnormalities 0 trials
- Neurodevelopmental disorder with hypotonia and dysmorphic facies 0 trials
- Neurodevelopmental disorder with hypotonia and gross motor and speech delay 0 trials
- Neurodevelopmental disorder with hypotonia and seizures 0 trials
- Neurodevelopmental disorder with hypotonia and speech delay, with or without seizures 0 trials
- Neurodevelopmental disorder with hypotonia and variable intellectual and behavioral abnormalities 0 trials
- Neurodevelopmental disorder with hypotonia, brain anomalies, distinctive facies, and absent language 0 trials
- Neurodevelopmental disorder with hypotonia, dysmorphic facies, and skeletal anomalies, with or without seizures 0 trials
- Neurodevelopmental disorder with hypotonia, dysmorphic facies, and skin abnormalities 0 trials
- Neurodevelopmental disorder with hypotonia, epilepsy, and absent speech 0 trials
- Neurodevelopmental disorder with hypotonia, facial dysmorphism, and brain abnormalities 0 trials
- Neurodevelopmental disorder with hypotonia, feeding difficulties, facial dysmorphism, and brain abnormalities 0 trials
- Neurodevelopmental disorder with hypotonia, impaired speech, and behavioral abnormalities 0 trials
- Neurodevelopmental disorder with hypotonia, language delay, and skeletal defects with or without seizures 0 trials
- Neurodevelopmental disorder with hypotonia, microcephaly, and seizures 0 trials
- Neurodevelopmental disorder with hypotonia, neonatal respiratory insufficiency, and thermodysregulation 0 trials
- Neurodevelopmental disorder with hypotonia, neuropathy, and deafness 0 trials
- Neurodevelopmental disorder with hypotonia, poor growth, dysmorphic facies, and agammaglobulinemia 0 trials
- Neurodevelopmental disorder with hypotonia, seizures, and absent language 0 trials
- Neurodevelopmental disorder with impaired intellectual development, hypotonia, and ataxia 0 trials
- Neurodevelopmental disorder with impaired language and ataxia and with or without seizures 0 trials
- Neurodevelopmental disorder with impaired language, behavioral abnormalities, and dysmorphic facies 0 trials
- Neurodevelopmental disorder with impaired speech and hyperkinetic movements 0 trials
- Neurodevelopmental disorder with infantile epileptic spasms 0 trials
- Neurodevelopmental disorder with intention tremor, pyramidal signs, dyspraxia, and ocular anomalies 0 trials
- Neurodevelopmental disorder with intracranial hemorrhage, seizures, and spasticity 0 trials
- Neurodevelopmental disorder with language delay and behavioral abnormalities, with or without seizures 0 trials
- Neurodevelopmental disorder with language delay and seizures 0 trials
- Neurodevelopmental disorder with language delay and variable cognitive abnormalities 0 trials
- Neurodevelopmental disorder with language impairment and behavioral abnormalities 0 trials
- Neurodevelopmental disorder with language impairment, autism, and attention deficit-hyperactivity disorder 0 trials
- Neurodevelopmental disorder with microcephaly and dysmorphic facies 0 trials
- Neurodevelopmental disorder with microcephaly and movement abnormalities 0 trials
- Neurodevelopmental disorder with microcephaly and speech delay, with or without brain abnormalities 0 trials
- Neurodevelopmental disorder with microcephaly and structural brain anomalies 0 trials
- Neurodevelopmental disorder with microcephaly, absent speech, and hypotonia 0 trials
- Neurodevelopmental disorder with microcephaly, arthrogryposis, and structural brain anomalies 0 trials
- Neurodevelopmental disorder with microcephaly, ataxia, and seizures 0 trials
- Neurodevelopmental disorder with microcephaly, cataracts, and renal abnormalities 0 trials
- Neurodevelopmental disorder with microcephaly, cerebral atrophy, and visual impairment 0 trials
- Neurodevelopmental disorder with microcephaly, cortical malformations, and spasticity 0 trials
- Neurodevelopmental disorder with microcephaly, epilepsy, and brain atrophy 0 trials
- Neurodevelopmental disorder with microcephaly, epilepsy, and hypomyelination 0 trials
- Neurodevelopmental disorder with microcephaly, hypotonia, and variable brain anomalies 0 trials
- Neurodevelopmental disorder with microcephaly, hypotonia, nystagmus, and seizures 0 trials
- Neurodevelopmental disorder with microcephaly, impaired language, and gait abnormalities 0 trials
- Neurodevelopmental disorder with microcephaly, impaired language, epilepsy, and gait abnormalities 0 trials
- Neurodevelopmental disorder with microcephaly, movement abnormalities, and seizures 0 trials
- Neurodevelopmental disorder with microcephaly, seizures, and brain atrophy 0 trials
- Neurodevelopmental disorder with microcephaly, seizures, and cortical atrophy 0 trials
- Neurodevelopmental disorder with microcephaly, seizures, and neonatal cholestasis 0 trials
- Neurodevelopmental disorder with microcephaly, short stature, and speech delay 0 trials
- Neurodevelopmental disorder with midbrain and hindbrain malformations 0 trials
- Neurodevelopmental disorder with motor abnormalities, seizures, and facial dysmorphism 0 trials
- Neurodevelopmental disorder with motor and language delay, ocular defects, and brain abnormalities 0 trials
- Neurodevelopmental disorder with motor and speech delay and behavioral abnormalities 0 trials
- Neurodevelopmental disorder with motor regression, progressive spastic paraplegia, and oromotor dysfunction 0 trials
- Neurodevelopmental disorder with movement abnormalities, abnormal gait, and autistic features 0 trials
- Neurodevelopmental disorder with neuromuscular and skeletal abnormalities 0 trials
- Neurodevelopmental disorder with nonspecific brain abnormalities and with or without seizures 0 trials
- Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart 0 trials
- Neurodevelopmental disorder with or without autism or seizures 0 trials
- Neurodevelopmental disorder with or without autistic features and/or structural brain abnormalities 0 trials
- Neurodevelopmental disorder with or without early-onset generalized epilepsy 0 trials
- Neurodevelopmental disorder with or without seizures and gait abnormalities 0 trials
- Neurodevelopmental disorder with or without variable movement or behavioral abnormalities 0 trials
- Neurodevelopmental disorder with poor growth and behavioral abnormalities 0 trials
- Neurodevelopmental disorder with poor growth and skeletal anomalies 0 trials
- Neurodevelopmental disorder with poor growth, large ears, and dysmorphic facies 0 trials
- Neurodevelopmental disorder with poor growth, seizures, and brain abnormalities 0 trials
- Neurodevelopmental disorder with poor language and loss of hand skills 0 trials
- Neurodevelopmental disorder with poor or absent speech, dysmorphic facies, and behavioral abnormalities 0 trials
- Neurodevelopmental disorder with progressive microcephaly, spasticity, and brain anomalies 0 trials
- Neurodevelopmental disorder with progressive movement abnormalities 0 trials
- Neurodevelopmental disorder with progressive spasticity and brain abnormalities 0 trials
- Neurodevelopmental disorder with progressive spasticity and brain white matter abnormalities 0 trials
- Neurodevelopmental disorder with regression, abnormal movements, loss of speech, and seizures 0 trials
- Neurodevelopmental disorder with relative macrocephaly and with or without cardiac or endocrine anomalies 0 trials
- Neurodevelopmental disorder with seizures and brain atrophy 0 trials
- Neurodevelopmental disorder with seizures and gingival overgrowth 0 trials
- Neurodevelopmental disorder with seizures and nonepileptic hyperkinetic movements 0 trials
- Neurodevelopmental disorder with seizures and speech and walking impairment 0 trials
- Neurodevelopmental disorder with seizures, hypotonia, and brain imaging abnormalities 0 trials
- Neurodevelopmental disorder with seizures, hypotonia, and variable spasticity 0 trials
- Neurodevelopmental disorder with seizures, microcephaly, and brain abnormalities 0 trials
- Neurodevelopmental disorder with seizures, spasticity, and complete or partial agenesis of the corpus callosum 0 trials
- Neurodevelopmental disorder with severe motor impairment and absent language 0 trials
- Neurodevelopmental disorder with severe motor impairment, absent language, cerebral hypomyelination, and brain atrophy 0 trials
- Neurodevelopmental disorder with short stature, prominent forehead, and feeding difficulties 0 trials
- Neurodevelopmental disorder with spastic quadriplegia and brain abnormalities with or without seizures 0 trials
- Neurodevelopmental disorder with spastic quadriplegia, optic atrophy, seizures, and structural brain anomalies 0 trials
- Neurodevelopmental disorder with spasticity and poor growth 0 trials
- Neurodevelopmental disorder with spasticity, cataracts, and cerebellar hypoplasia 0 trials
- Neurodevelopmental disorder with spasticity, seizures, and brain abnormalities 0 trials
- Neurodevelopmental disorder with spasticity, thin corpus callosum, and decreased brain white matter 0 trials
- Neurodevelopmental disorder with speech delay and behavioral abnormalities 0 trials
- Neurodevelopmental disorder with speech delay and variable ocular anomalies 0 trials
- Neurodevelopmental disorder with speech delay, movement abnormalities, and seizures 0 trials
- Neurodevelopmental disorder with speech impairment and dysmorphic facies 0 trials
- Neurodevelopmental disorder with speech impairment and with or without seizures 0 trials
- Neurodevelopmental disorder with speech or visual impairment and brain hypomyelination 0 trials
- Neurodevelopmental disorder with structural brain abnormalities and craniofacial abnormalities 0 trials
- Neurodevelopmental disorder with structural brain anomalies and dysmorphic facies 0 trials
- Neurodevelopmental disorder with thin corpus callosum, hypotonia, and absent language 0 trials
- Neurodevelopmental disorder with variable familial hypercholanemia 0 trials
- Neurodevelopmental disorder with visual defects and brain anomalies 0 trials
- Neurodevelopmental disorder with white matter abnormalities and gait disturbance 0 trials
- Neurodevelopmental disorder, mitochondrial, with abnormal movements and lactic acidosis, with or without seizures 0 trials
- Neurodevelopmental disorder, nonprogressive, with spasticity and transient opisthotonus 0 trials
- Otofacial neurodevelopmental syndrome 0 trials
- Parenti-mignot neurodevelopmental syndrome 0 trials
- Squalene synthase deficiency 0 trials
-
Obsessive-compulsive disorder 196 trials
-
Hereditary ataxia 2 trials · 119 incl. sub-types
20 sub-types
- Hereditary cerebellar ataxia 0 trials · 116 incl. sub-types Sub-types →
- Spastic ataxia 1 trial · 2 incl. sub-types Sub-types →
- EAST syndrome 1 trial
- Hereditary episodic ataxia 0 trials · 1 incl. sub-types Sub-types →
- Hereditary spastic paraplegia 7 1 trial
- Richards-Rundle syndrome 0 trials
- Ataxia with fasciculations 0 trials
- Ataxia-hypogonadism-choroidal dystrophy syndrome 0 trials
- Ataxia-tapetoretinal degeneration syndrome 0 trials
- Autosomal dominant sensory ataxia 1 0 trials
- Autosomal recessive ataxia due to PEX16 deficiency 0 trials
- Autosomal recessive ataxia due to PEX2 deficiency 0 trials
- Cataract-ataxia-deafness syndrome 0 trials
- Ichthyosis-hepatosplenomegaly-cerebellar degeneration syndrome 0 trials
- Juvenile-onset diabetes mellitus-central and peripheral neurodegeneration syndrome 0 trials
- Muscular atrophy-ataxia-retinitis pigmentosa-diabetes mellitus syndrome 0 trials
- Myoclonus-cerebellar ataxia-deafness syndrome 0 trials
- Severe microbrachycephaly-intellectual disability-athetoid cerebral palsy syndrome 0 trials
- Spinocerebellar ataxia-dysmorphism syndrome 0 trials
- Tremor-ataxia-central hypomyelination syndrome 0 trials
-
Essential tremor 102 trials · 104 incl. sub-types
6 sub-types
- Tremor, hereditary essential, 1 2 trials
- Tremor, hereditary essential, 2 0 trials
- Tremor, hereditary essential, 3 0 trials
- Tremor, hereditary essential, 4 0 trials
- Tremor, hereditary essential, 5 0 trials
- Tremor, hereditary essential, 6 0 trials
-
Neurofibromatosis 19 trials · 94 incl. sub-types
5 sub-types
- Neurofibromatosis type 1 73 trials Sub-types →
- NF2-related schwannomatosis 21 trials
- Schwannomatosis 3 trials Sub-types →
- Neurofibromatosis-Noonan syndrome 2 trials Sub-types →
- Neurofibromatosis, type IV, of Riccardi 0 trials
-
Inherited orthostatic hypotension 0 trials · 71 incl. sub-types
3 sub-types
- Postural orthostatic tachycardia syndrome 71 trials
- Orthostatic hypotension 1 0 trials
- Orthostatic hypotension 2 0 trials
-
Nonsyndromic genetic hearing loss 4 trials · 67 incl. sub-types
6 sub-types
- Prelingual non-syndromic genetic hearing loss 5 trials · 37 incl. sub-types Sub-types →
- X-linked nonsyndromic hearing loss 0 trials · 32 incl. sub-types Sub-types →
- Hearing loss, autosomal recessive 1 trial · 17 incl. sub-types Sub-types →
- Postlingual non-syndromic genetic hearing loss 6 trials · 10 incl. sub-types Sub-types →
- Autosomal dominant nonsyndromic hearing loss 1 trial · 2 incl. sub-types Sub-types →
- Nonsyndromic deafness, Y-linked 0 trials Sub-types →
-
Inherited vitreoretinopathy 0 trials · 58 incl. sub-types
5 sub-types
- Vitreoretinal degeneration 0 trials · 45 incl. sub-types Sub-types →
- Congenital vitreoretinal dysplasia 0 trials · 9 incl. sub-types Sub-types →
- Vitreous detachment 5 trials
- NDP-related vitreoretinopathy 0 trials Sub-types →
- TSPAN12-related vitreoretinopathy 0 trials Sub-types →
-
Paraganglioma 53 trials · 57 incl. sub-types
12 sub-types
- Sympathetic paraganglioma 0 trials · 16 incl. sub-types Sub-types →
- Head and neck paraganglioma 1 trial Sub-types →
- Non-secreting paraganglioma 0 trials Sub-types →
- Parasympathetic paraganglioma 0 trials Sub-types →
- Pheochromocytoma/paraganglioma syndrome 1 0 trials
- Pheochromocytoma/paraganglioma syndrome 2 0 trials
- Pheochromocytoma/paraganglioma syndrome 3 0 trials
- Pheochromocytoma/paraganglioma syndrome 4 0 trials
- Pheochromocytoma/paraganglioma syndrome 5 0 trials
- Pheochromocytoma/paraganglioma syndrome 6 0 trials
- Pheochromocytoma/paraganglioma syndrome 7 0 trials
- Sporadic pheochromocytoma/secreting paraganglioma 0 trials Sub-types →
-
Retinal detachment 28 trials · 52 incl. sub-types
2 sub-types
- Rhegmatogenous retinal detachment 23 trials Sub-types →
- Retinal perforation 18 trials
-
Tuberous sclerosis 41 trials · 44 incl. sub-types
2 sub-types
- Tuberous sclerosis 1 33 trials
- Tuberous sclerosis 2 2 trials
-
Endogenous depression 42 trials
-
Specific phobia 22 trials · 42 incl. sub-types
3 sub-types
- Nosophobia 2 trials · 16 incl. sub-types Sub-types →
- Animal phobia 5 trials
- Flying phobia 1 trial
-
Combined pituitary hormone deficiencies, genetic form 1 trial · 42 incl. sub-types
9 sub-types
- Isolated congenital growth hormone deficiency 38 trials Sub-types →
- Panhypopituitarism 2 trials Sub-types →
- Congenital isolated adrenocorticotropic hormone deficiency 1 trial
- Pituitary hormone deficiency, combined, 1 1 trial
- Septooptic dysplasia 1 trial Sub-types →
- Non-acquired combined pituitary hormone deficiency with spine abnormalities 0 trials
- Pituitary hormone deficiency, combined or isolated, 8 0 trials
- Pituitary hormone deficiency, combined, 6 0 trials
- Short stature-pituitary and cerebellar defects-small sella turcica syndrome 0 trials
-
Tourette syndrome 41 trials
-
Familial partial epilepsy 0 trials · 39 incl. sub-types
7 sub-types
- Temporal lobe epilepsy 31 trials Sub-types →
- Mesial temporal lobe epilepsy with hippocampal sclerosis 10 trials
- Self-limited epilepsy with centrotemporal spikes 3 trials Sub-types →
- Generalized epilepsy-paroxysmal dyskinesia syndrome 1 trial
- Autosomal dominant epilepsy with auditory features 0 trials
- Familial focal epilepsy with variable foci 0 trials Sub-types →
- Familial sleep-related hypermotor epilepsy 0 trials Sub-types →
-
Cerebral lipidosis with dementia 0 trials · 38 incl. sub-types
8 sub-types
- Sandhoff disease 13 trials Sub-types →
- Tay-Sachs disease 13 trials Sub-types →
- Gaucher disease type I 12 trials
- Cerebrotendinous xanthomatosis 6 trials
- Juvenile neuronal ceroid lipofuscinosis 6 trials Sub-types →
- Adult Krabbe disease 0 trials
- Adult neuronal ceroid lipofuscinosis 0 trials Sub-types →
- Infantile neuronal ceroid lipofuscinosis 0 trials Sub-types →
-
Inherited dystonia 0 trials · 36 incl. sub-types
24 sub-types
- Combined dystonia 1 trial · 12 incl. sub-types Sub-types →
- Isolated dystonia 4 trials · 11 incl. sub-types Sub-types →
- Lymphatic malformation 5 8 trials
- Dystonia, focal, task-specific 4 trials
- Dopa-responsive dystonia due to sepiapterin reductase deficiency 1 trial
- Dystonia 28, childhood-onset 1 trial
- Torsion dystonia 7 1 trial
- Woodhouse-Sakati syndrome 0 trials
- Ataxia - oculomotor apraxia type 4 0 trials
- Autosomal dominant dopa-responsive dystonia 0 trials Sub-types →
- Developmental malformations-deafness-dystonia syndrome 0 trials
- Dystonia 22, adult-onset 0 trials
- Dystonia 22, juvenile-onset 0 trials
- Dystonia 30 0 trials
- Dystonia 31 0 trials
- Dystonia 32 0 trials
- Dystonia 33 0 trials
- Dystonia 34, myoclonic 0 trials
- Dystonia 35, childhood-onset 0 trials
- Dystonia 37, early-onset, with striatal lesions 0 trials
- Dystonia, childhood-onset, with optic atrophy and basal ganglia abnormalities 0 trials
- Familial idiopathic torsion dystonia 0 trials
- Severe motor and intellectual disabilities-sensorineural deafness-dystonia syndrome 0 trials
- Striatonigral degeneration, childhood-onset 0 trials
-
Normal pressure hydrocephalus 35 trials
-
Mismatch repair cancer syndrome 1 34 trials
-
Hereditary generalized epilepsy 0 trials · 33 incl. sub-types
2 sub-types
- Idiopathic generalized epilepsy 11 trials · 29 incl. sub-types Sub-types →
- Generalized epilepsy with febrile seizures plus 0 trials · 4 incl. sub-types Sub-types →
-
X-linked deafness 0 trials · 32 incl. sub-types
2 sub-types
- X-linked nonsyndromic hearing loss 0 trials · 32 incl. sub-types Sub-types →
- X-linked external auditory canal atresia-dilated internal auditory canal-facial dysmorphism syndrome 0 trials
-
Familial isolated pituitary adenoma 1 trial · 31 incl. sub-types
6 sub-types
- Cushing disease due to pituitary adenoma 23 trials
- Prolactin-producing pituitary gland adenoma 11 trials
- Growth hormone secreting pituitary adenoma 1 1 trial
- Pituitary adenoma 3, multiple types 0 trials
- Pituitary adenoma 5, multiple types 0 trials
- Pituitary adenoma, growth hormone-secreting, 2 0 trials
-
Von Hippel-Lindau disease 27 trials
-
Specific language impairment 26 trials
5 sub-types
- Specific language impairment 1 0 trials
- Specific language impairment 2 0 trials
- Specific language impairment 3 0 trials
- Specific language impairment 4 0 trials
- Specific language impairment 5 0 trials
-
Stutter disorder 22 trials
4 sub-types
- Stuttering, familial persistent, 1 0 trials
- Stuttering, familial persistent, 2 0 trials
- Stuttering, familial persistent, 3 0 trials
- Stuttering, familial persistent, 4 0 trials
-
Moyamoya disease 20 trials
8 sub-types
- Moyamoya disease 2 0 trials
- Moyamoya disease 5 0 trials
- Moyamoya disease 8 0 trials
- Moyamoya disease with early-onset achalasia 0 trials
- Moyamoya angiopathy-short stature-facial dysmorphism-hypergonadotropic hypogonadism syndrome 0 trials
- Moyamoya disease 1 0 trials
- Moyamoya disease 3 0 trials
- Moyamoya disease 7 0 trials
-
Angelman syndrome 19 trials
-
Cerebral amyloid angiopathy 16 trials · 17 incl. sub-types
4 sub-types
- ACys amyloidosis 1 trial
- Cerebral amyloid angiopathy, APP-related 0 trials · 1 incl. sub-types Sub-types →
- ABri amyloidosis 0 trials
- ADan amyloidosis 0 trials
-
Li-Fraumeni syndrome 16 trials
-
Childhood apraxia of speech 16 trials
-
Intracranial berry aneurysm 12 trials
12 sub-types
- Aneurysm, intracranial berry type 1 0 trials
- Aneurysm, intracranial berry, 10 0 trials
- Aneurysm, intracranial berry, 11 0 trials
- Aneurysm, intracranial berry, 12 0 trials
- Aneurysm, intracranial berry, 2 0 trials
- Aneurysm, intracranial berry, 3 0 trials
- Aneurysm, intracranial berry, 4 0 trials
- Aneurysm, intracranial berry, 5 0 trials
- Aneurysm, intracranial berry, 6 0 trials
- Aneurysm, intracranial berry, 7 0 trials
- Aneurysm, intracranial berry, 8 0 trials
- Aneurysm, intracranial berry, 9 0 trials
-
Progressive myoclonus epilepsy 5 trials · 12 incl. sub-types
15 sub-types
- MERRF syndrome 5 trials
- Lafora disease 1 trial Sub-types →
- Unverricht-Lundborg syndrome 1 trial
- Neuronal ceroid lipofuscinosis 8 northern epilepsy variant 1 trial
- Action myoclonus-renal failure syndrome 0 trials
- Early-onset Lafora body disease 0 trials
- Epilepsy, progressive myoclonic, 11 0 trials
- Epilepsy, progressive myoclonic, 12 0 trials
- Epilepsy, progressive myoclonic, 1B 0 trials
- Familial encephalopathy with neuroserpin inclusion bodies 0 trials
- Progressive myoclonic epilepsy type 3 0 trials
- Progressive myoclonic epilepsy type 6 0 trials
- Progressive myoclonic epilepsy type 7 0 trials
- Progressive myoclonic epilepsy type 8 0 trials
- Progressive myoclonic epilepsy type 9 0 trials
-
DiGeorge syndrome 11 trials
-
Major affective disorder 6 11 trials
-
Auditory neuropathy 7 trials · 11 incl. sub-types
5 sub-types
-
Spastic quadriplegic cerebral palsy 10 trials
-
Chiari malformation type I 9 trials
-
Neurohypophyseal diabetes insipidus 9 trials
-
Sturge-Weber syndrome 8 trials
-
Progressive external ophthalmoplegia 4 trials · 8 incl. sub-types
3 sub-types
- Kearns-Sayre syndrome 5 trials
- Progressive external ophthalmoplegia with mitochondrial DNA deletions 0 trials · 2 incl. sub-types Sub-types →
- Autosomal recessive progressive external ophthalmoplegia 0 trials Sub-types →
-
Qualitative or quantitative defects of protein involved in O-glycosylation of alpha-dystroglycan 0 trials · 8 incl. sub-types
9 sub-types
- Qualitative or quantitative defects of FKRP 0 trials · 8 incl. sub-types Sub-types →
- Myopathy caused by variation in FKTN 1 trial · 2 incl. sub-types Sub-types →
- Myopathy caused by variation in CRPPA 0 trials · 1 incl. sub-types Sub-types →
- Myopathy caused by variation in GMPPB 0 trials · 1 incl. sub-types Sub-types →
- Myopathy caused by variation in POMT1 0 trials · 1 incl. sub-types Sub-types →
- Myopathy caused by variation in POMT2 0 trials · 1 incl. sub-types Sub-types →
- Qualitative or quantitative defects of protein O-mannosyltransferase 1 0 trials · 1 incl. sub-types Sub-types →
- Qualitative or quantitative defects of protein O-mannosyltransferase 2 0 trials · 1 incl. sub-types Sub-types →
- Limb-girdle muscular dystrophy due to POMK deficiency 0 trials
-
Red-green color blindness 7 trials
-
Duane retraction syndrome 6 trials
4 sub-types
- Duane retraction syndrome 2 0 trials
- Duane retraction syndrome 3 with or without deafness 0 trials
- Duane retraction syndrome with congenital deafness 0 trials
- Duane syndrome type 1 0 trials
-
Arthrogryposis 4 trials · 6 incl. sub-types
5 sub-types
- Freeman-Sheldon syndrome 1 trial Sub-types →
- Congenital contractural arachnodactyly 1 trial
- Boylan dew greco syndrome 0 trials
- Distal arthrogryposis Moore weaver type 0 trials
- Massa casaer ceulemans syndrome 0 trials
-
Undetermined early-onset epileptic encephalopathy 1 trial · 6 incl. sub-types
16 sub-types
- Developmental and epileptic encephalopathy, 13 3 trials
- Developmental and epileptic encephalopathy, 25 1 trial
- Developmental and epileptic encephalopathy, 42 1 trial
- Developmental and epileptic encephalopathy, 21 0 trials
- Developmental and epileptic encephalopathy, 24 0 trials
- Developmental and epileptic encephalopathy, 26 0 trials
- Developmental and epileptic encephalopathy, 28 0 trials
- Developmental and epileptic encephalopathy, 29 0 trials
- Developmental and epileptic encephalopathy, 31A 0 trials
- Developmental and epileptic encephalopathy, 32 0 trials
- Developmental and epileptic encephalopathy, 33 0 trials
- Developmental and epileptic encephalopathy, 41 0 trials
- Developmental and epileptic encephalopathy, 44 0 trials
- Developmental and epileptic encephalopathy, 45 0 trials
- Developmental and epileptic encephalopathy, 46 0 trials
- Developmental and epileptic encephalopathy, 47 0 trials
-
Inborn aminoacylase deficiency 0 trials · 6 incl. sub-types
2 sub-types
- Canavan disease 6 trials Sub-types →
- Aminoacylase 1 deficiency 0 trials
-
Narcolepsy 1 5 trials
-
Nevoid basal cell carcinoma syndrome 5 trials
2 sub-types
- Basal cell nevus syndrome 1 0 trials
- Basal cell nevus syndrome 2 0 trials
-
GLUT1 deficiency syndrome 4 trials · 5 incl. sub-types
2 sub-types
-
Congenital nystagmus 4 trials · 5 incl. sub-types
10 sub-types
- Spinocerebellar ataxia 27A 1 trial
- Nystagmus 1, congenital, X-linked 0 trials
- Nystagmus 2, congenital, autosomal dominant 0 trials
- Nystagmus 3, congenital, autosomal dominant 0 trials
- Nystagmus 5, congenital, X-linked 0 trials
- Nystagmus 6, congenital, X-linked 0 trials
- Nystagmus 7, congenital, autosomal dominant 0 trials
- Nystagmus, congenital, autosomal recessive 0 trials
- Nystagmus, hereditary vertical 0 trials
- Nystagmus, myoclonic 0 trials
-
Congenital stationary night blindness 2 trials · 5 incl. sub-types
14 sub-types
- Congenital stationary night blindness autosomal dominant 1 3 trials
- Congenital stationary night blindness autosomal dominant 2 1 trial
- Oguchi disease 0 trials Sub-types →
- X-linked congenital stationary night blindness 0 trials Sub-types →
- Cone-rod synaptic disorder, congenital nonprogressive 0 trials
- Congenital stationary night blindness 1B 0 trials
- Congenital stationary night blindness 1C 0 trials
- Congenital stationary night blindness 1D 0 trials
- Congenital stationary night blindness 1E 0 trials
- Congenital stationary night blindness 1F 0 trials
- Congenital stationary night blindness 1G 0 trials
- Congenital stationary night blindness 1H 0 trials
- Congenital stationary night blindness autosomal dominant 3 0 trials
- Night blindness, congenital stationary, type1i 0 trials
-
Qualitative or quantitative defects of beta-sarcoglycan 0 trials · 5 incl. sub-types
1 sub-type
-
Corpus callosum, agenesis of 4 trials
2 sub-types
- Kozlowski Ouvrier syndrome 0 trials
- Calloso-genital dysplasia 0 trials
-
Velocardiofacial syndrome 4 trials
-
TTN-related myopathy 2 trials · 4 incl. sub-types
2 sub-types
- Autosomal recessive titinopathy 0 trials · 2 incl. sub-types Sub-types →
- Autosomal dominant titinopathy 0 trials Sub-types →
-
Qualitative or quantitative defects of gamma-sarcoglycan 1 trial · 4 incl. sub-types
1 sub-type
-
Hoyeraal-Hreidarsson syndrome 3 trials
-
Riley-Day syndrome 3 trials
-
Bilirubin encephalopathy 3 trials
1 sub-type
- Kernicterus due to isoimmunization 0 trials
-
Familial congenital mirror movements 3 trials
4 sub-types
- Mirror movements 1 and/or agenesis of the corpus callosum 0 trials Sub-types →
- Mirror movements 2 0 trials
- Mirror movements 3 0 trials
- Mirror movements 4 0 trials
-
Pyridoxine-dependent epilepsy 3 trials
2 sub-types
-
Encephalopathy, acute, infection-induced 2 trials · 3 incl. sub-types
1 sub-type
-
TPM2-related myopathy 1 trial · 3 incl. sub-types
2 sub-types
- Central core myopathy 2 trials
- Congenital myopathy 23 0 trials
-
Congenital hydrocephalus 1 trial · 3 incl. sub-types
8 sub-types
- X-linked hydrocephalus with stenosis of the aqueduct of Sylvius 1 trial
- Hydrocephalus, nonsyndromic, autosomal recessive 1 1 trial
- Autosomal recessive hydrocephalus due to congenital stenosis of aqueduct of Sylvius 0 trials
- Congenital communicating hydrocephalus 0 trials
- Congenital non-communicating hydrocephalus 0 trials
- Hydrocephalus, congenital, 3, with brain anomalies 0 trials
- Hydrocephalus, nonsyndromic, autosomal recessive 2 0 trials
- Hydrocephalus-blue sclerae-nephropathy syndrome 0 trials
-
Pontocerebellar hypoplasia 1 trial · 3 incl. sub-types
21 sub-types
- Pontocerebellar hypoplasia type 6 2 trials
- Pontocerebellar hypoplasia type 1 0 trials Sub-types →
- Pontocerebellar hypoplasia type 10 0 trials
- Pontocerebellar hypoplasia type 2 0 trials Sub-types →
- Pontocerebellar hypoplasia type 2E 0 trials
- Pontocerebellar hypoplasia type 3 0 trials
- Pontocerebellar hypoplasia type 4 0 trials
- Pontocerebellar hypoplasia type 5 0 trials
- Pontocerebellar hypoplasia type 7 0 trials
- Pontocerebellar hypoplasia type 8 0 trials
- Pontocerebellar hypoplasia type 9 0 trials
- Pontocerebellar hypoplasia, IIA 17 0 trials
- Pontocerebellar hypoplasia, type 11 0 trials
- Pontocerebellar hypoplasia, type 12 0 trials
- Pontocerebellar hypoplasia, type 13 0 trials
- Pontocerebellar hypoplasia, type 14 0 trials
- Pontocerebellar hypoplasia, type 15 0 trials
- Pontocerebellar hypoplasia, type 16 0 trials
- Pontocerebellar hypoplasia, type 1D 0 trials
- Pontocerebellar hypoplasia, type 1E 0 trials
- Pontocerebellar hypoplasia, type 1F 0 trials
-
Familial porencephaly 0 trials · 3 incl. sub-types
7 sub-types
- Brain small vessel disease 1 with or without ocular anomalies 3 trials
- Brain small vessel disease 2A, autosomal dominant 1 trial
- Brain small vessel disease 2B, autosomal recessive 0 trials
- Brain small vessel disease 3 0 trials
- Brain small vessel disease 4 0 trials
- Brain small vessel disease 5 with osteoporosis 0 trials
- Brain small vessel disease 6 with leukoencephalopathy 0 trials
-
Inherited reflex epilepsy 0 trials · 3 incl. sub-types
2 sub-types
- Photosensitive epilepsy 1 trial · 2 incl. sub-types Sub-types →
- Hot water reflex epilepsy 1 trial Sub-types →
-
Neuromuscular disease caused by qualitative or quantitative defects of dysferlin 0 trials · 3 incl. sub-types
4 sub-types
-
Qualitative or quantitative defects of alpha-sarcoglycan 0 trials · 3 incl. sub-types
1 sub-type
-
Chiari malformation type II 2 trials
-
Central nervous system lupus 2 trials
-
Choroid plexus papilloma 2 trials
-
Hereditary retinoblastoma 2 trials
-
1 sub-type
-
Childhood-onset nemaline myopathy 1 trial · 2 incl. sub-types
6 sub-types
- Nemaline myopathy 6 1 trial
- Congenital myopathy 23 0 trials
- Congenital myopathy 2a, typical, autosomal dominant 0 trials
- Congenital myopathy 4B, autosomal recessive 0 trials
- Nemaline myopathy 2 0 trials
- Nemaline myopathy 9 0 trials
-
ATP1A3-associated neurological disorder 0 trials · 2 incl. sub-types
4 sub-types
-
PAX6-related ocular dysgenesis 0 trials · 2 incl. sub-types
2 sub-types
- Isolated optic nerve hypoplasia 2 trials
- Foveal hypoplasia 1 0 trials
-
SPAST-related motor disorder 0 trials · 2 incl. sub-types
1 sub-type
- Hereditary spastic paraplegia 4 2 trials
-
Leukoencephalopathy, megalencephalic 0 trials · 2 incl. sub-types
-
Qualitative or quantitative defects of delta-sarcoglycan 0 trials · 2 incl. sub-types
2 sub-types
-
Retinal ciliopathy 0 trials · 2 incl. sub-types
9 sub-types
- Leber congenital amaurosis 10 2 trials
- Leber congenital amaurosis with early-onset deafness 0 trials
- Cone-rod dystrophy 16 0 trials
- Retinitis pigmentosa 23 0 trials
- Retinitis pigmentosa 51 0 trials
- Retinitis pigmentosa 55 0 trials
- Retinitis pigmentosa 64 0 trials
- Retinitis pigmentosa 74 0 trials
- Retinitis pigmentosa 80 0 trials
-
Brown syndrome 1 trial
-
TPM3-related myopathy 1 trial
3 sub-types
- Cap myopathy 0 trials
- Congenital myopathy 4A, autosomal dominant 0 trials
- Congenital myopathy 4B, autosomal recessive 0 trials
-
Anencephaly 1 trial
4 sub-types
- Anencephaly 1 0 trials
- Anencephaly 2 0 trials
- Hydranencephaly 0 trials Sub-types →
- Isolated anencephaly 0 trials
-
10 sub-types
- Basal ganglia calcification, idiopathic, 1 0 trials
- Basal ganglia calcification, idiopathic, 10, autosomal recessive 0 trials
- Basal ganglia calcification, idiopathic, 11, autosomal recessive 0 trials
- Basal ganglia calcification, idiopathic, 4 0 trials
- Basal ganglia calcification, idiopathic, 5 0 trials
- Basal ganglia calcification, idiopathic, 6 0 trials
- Basal ganglia calcification, idiopathic, 7, autosomal recessive 0 trials
- Basal ganglia calcification, idiopathic, 8, autosomal recessive 0 trials
- Basal ganglia calcification, idiopathic, 9, autosomal recessive 0 trials
- Basal ganglia calcification, idiopathic, childhood-onset 0 trials
-
Coloboma of optic nerve 1 trial
1 sub-type
- Morning glory syndrome 0 trials
-
Dilated cardiomyopathy 3B 1 trial
-
Familial meningioma 1 trial
-
5 sub-types
- Cerebral cavernous malformation 1 1 trial
- Cerebral cavernous malformation 2 0 trials
- Cerebral cavernous malformation 3 0 trials
- Cerebral cavernous malformation 4 0 trials
- Cerebral cavernous malformations 5 0 trials
-
Iris hypoplasia with glaucoma 1 trial
-
Linear nevus sebaceous syndrome 1 trial
-
Multiminicore myopathy 1 trial
5 sub-types
- Rigid spine muscular dystrophy 1 1 trial Sub-types →
- Antenatal multiminicore disease with arthrogryposis multiplex congenita 0 trials
- Classic multiminicore myopathy 0 trials
- Congenital multicore myopathy with external ophthalmoplegia 0 trials
- Moderate multiminicore disease with hand involvement 0 trials
-
Myoclonus, familial 1 trial
2 sub-types
- Myoclonus, familial, 1 0 trials
- Myoclonus, familial, 2 0 trials
-
Neurocutaneous melanocytosis 1 trial
-
2-hydroxyglutaric aciduria 0 trials · 1 incl. sub-types
3 sub-types
- D,L-2-hydroxyglutaric aciduria 1 trial
- D-2-hydroxyglutaric aciduria 0 trials Sub-types →
- L-2-hydroxyglutaric aciduria 0 trials
-
PRRT2-associated paroxysmal movement disorder 0 trials · 1 incl. sub-types
3 sub-types
- Episodic kinesigenic dyskinesia 1 1 trial
- Infantile convulsions and choreoathetosis 0 trials
- Seizures, benign familial infantile, 2 0 trials
-
Familial hemiplegic migraine 0 trials · 1 incl. sub-types
5 sub-types
-
Familial periodic paralysis 0 trials · 1 incl. sub-types
6 sub-types
- Hyperkalemic periodic paralysis 1 trial
- Hypokalemic periodic paralysis 1 trial Sub-types →
- Andersen-Tawil syndrome 0 trials
- Normokalemic periodic paralysis 0 trials
- Periodic paralysis with later-onset distal motor neuropathy 0 trials
- Thyrotoxic periodic paralysis 0 trials
-
Myopathy caused by variation in POMGNT1 0 trials · 1 incl. sub-types
-
Neuromuscular disease caused by qualitative or quantitative defects of plectin 0 trials · 1 incl. sub-types
2 sub-types
-
Neuromuscular disease caused by qualitative or quantitative defects of telethonin 0 trials · 1 incl. sub-types
2 sub-types
-
Qualitative or quantitative defects of desmin 0 trials · 1 incl. sub-types
5 sub-types
- Rigid spine syndrome 0 trials · 1 incl. sub-types Sub-types →
- Autosomal dominant limb-girdle muscular dystrophy type 1E (DES) 0 trials
- Dilated cardiomyopathy 1I 0 trials
- Myofibrillar myopathy 1 0 trials
- Neurogenic scapuloperoneal syndrome, Kaeser type 0 trials
-
Severe congenital nemaline myopathy 0 trials · 1 incl. sub-types
5 sub-types
- Nemaline myopathy 8 1 trial
- Congenital myopathy 2a, typical, autosomal dominant 0 trials
- Nemaline myopathy 10 0 trials
- Nemaline myopathy 2 0 trials
- Nemaline myopathy 9 0 trials
-
Bailey-Bloch congenital myopathy 0 trials
-
Behr syndrome 0 trials
-
Behrens Baumann dust syndrome 0 trials
-
Brody myopathy 0 trials
-
DHDDS-related syndrome 0 trials
2 sub-types
-
Frey syndrome 0 trials
-
Griscelli syndrome type 1 0 trials
-
HSD10 mitochondrial disease 0 trials
3 sub-types
- HSD10 disease, atypical type 0 trials
- HSD10 disease, infantile type 0 trials
- HSD10 disease, neonatal type 0 trials
-
Johanson-Blizzard syndrome 0 trials
-
KIF5A-related neurological disorder 0 trials
3 sub-types
-
NPHP3-related Meckel-like syndrome 0 trials
-
PEHO-like syndrome 0 trials
-
PrP systemic amyloidosis 0 trials
-
Prader-Willi-like syndrome 0 trials
3 sub-types
- 6q16 deletion syndrome 0 trials
- BDV syndrome 0 trials
- SIM1-related Prader-Willi-like syndrome 0 trials
-
Ritscher-Schinzel syndrome 0 trials
4 sub-types
- Ritscher-Schinzel syndrome 1 0 trials
- Ritscher-Schinzel syndrome 2 0 trials
- Ritscher-Schinzel syndrome 3 0 trials
- Ritscher-Schinzel syndrome 4 0 trials
-
SERAC1-related neurological disorder 0 trials
-
SLC39A8-CDG 0 trials
-
2 sub-types
-
TUBB3-related tubulinopathy 0 trials
-
Uner Tan Syndrome 0 trials
-
VPS11-related neurological disorder 0 trials
2 sub-types
- Dystonia 32 0 trials
- Hypomyelinating leukodystrophy 12 0 trials
-
X-linked immunoneurologic disorder 0 trials
-
Achromatopsia 6 0 trials
-
Adult-onset nemaline myopathy 0 trials
-
Age-related hearing impairment 1 0 trials
-
Age-related hearing impairment 2 0 trials
-
Alpha-actinopathy 0 trials
4 sub-types
- Cap myopathy 0 trials
- Congenital myopathy 2a, typical, autosomal dominant 0 trials
- Progressive scapulohumeroperoneal distal myopathy 0 trials
- Zebra body myopathy 0 trials
-
Angioid streaks 0 trials
1 sub-type
- Angioid streaks of choroid 0 trials
-
Aniridia 2 0 trials
-
Aniridia 3 0 trials
-
Band heterotopia of brain 0 trials
-
Benign familial infantile epilepsy 0 trials
5 sub-types
-
Benign neonatal seizures 0 trials
4 sub-types
-
Bilateral generalized polymicrogyria 0 trials
-
Blue color blindness 0 trials
-
Bradyopsia 0 trials
2 sub-types
-
Brain-lung-thyroid syndrome 0 trials
-
Caveolinopathy 0 trials
1 sub-type
-
Cerebellar-facial-dental syndrome 0 trials
-
Choreoathetosis, familial inverted 0 trials
-
Cluster headache, familial 0 trials
-
12 sub-types
- Complex cortical dysplasia with other brain malformations 1 0 trials
- Complex cortical dysplasia with other brain malformations 2 0 trials
- Complex cortical dysplasia with other brain malformations 3 0 trials
- Complex cortical dysplasia with other brain malformations 4 0 trials
- Complex cortical dysplasia with other brain malformations 5 0 trials
- Complex cortical dysplasia with other brain malformations 6 0 trials
- Complex cortical dysplasia with other brain malformations 7 0 trials
- Cortical dysplasia, complex, with other brain malformations 10 0 trials
- Cortical dysplasia, complex, with other brain malformations 11 0 trials
- Cortical dysplasia, complex, with other brain malformations 12 0 trials
- Cortical dysplasia, complex, with other brain malformations 9 0 trials
- Polymicrogyria with optic nerve hypoplasia 0 trials
-
Encephalopathy, acute transient 0 trials
-
Epilepsy, familial adult myoclonic 0 trials
8 sub-types
- Benign adult familial myoclonic epilepsy 0 trials
- Epilepsy, familial adult myoclonic, 1 0 trials
- Epilepsy, familial adult myoclonic, 2 0 trials
- Epilepsy, familial adult myoclonic, 3 0 trials
- Epilepsy, familial adult myoclonic, 4 0 trials
- Epilepsy, familial adult myoclonic, 5 0 trials
- Epilepsy, familial adult myoclonic, 6 0 trials
- Epilepsy, familial adult myoclonic, 7 0 trials
-
Familial hyperprolactinemia 0 trials
-
Familial panic disorder 0 trials
3 sub-types
- Panic disorder 1 0 trials
- Panic disorder 2 0 trials
- Panic disorder 3 0 trials
-
Familial schizencephaly 0 trials
-
Familial syringomyelia 0 trials
-
Febrile seizures, familial, 11 0 trials
-
Folinic acid-responsive seizures 0 trials
-
Glycine encephalopathy 0 trials
5 sub-types
- Atypical glycine encephalopathy 0 trials
- Glycine encephalopathy 1 0 trials
- Glycine encephalopathy 2 0 trials
- Infantile glycine encephalopathy 0 trials
- Neonatal glycine encephalopathy 0 trials
-
Hereditary hyperekplexia 0 trials
5 sub-types
- Developmental and epileptic encephalopathy, 8 0 trials
- Hyperekplexia 1 0 trials
- Hyperekplexia 2 0 trials
- Hyperekplexia 3 0 trials
- Hyperekplexia 4 0 trials
-
Holoprosencephaly 0 trials
17 sub-types
- Alobar holoprosencephaly 0 trials Sub-types →
- Chromosome 1q41-q42 deletion syndrome 0 trials
- Holoprosencephaly 1 0 trials
- Holoprosencephaly 10 0 trials
- Holoprosencephaly 11 0 trials
- Holoprosencephaly 12 with or without pancreatic agenesis 0 trials
- Holoprosencephaly 13, X-linked 0 trials
- Holoprosencephaly 14 0 trials
- Holoprosencephaly 2 0 trials
- Holoprosencephaly 3 0 trials Sub-types →
- Holoprosencephaly 4 0 trials
- Holoprosencephaly 6 0 trials
- Holoprosencephaly 7 0 trials
- Holoprosencephaly 8 0 trials
- Lobar holoprosencephaly 0 trials Sub-types →
- Microform holoprosencephaly 0 trials Sub-types →
- Semilobar holoprosencephaly 0 trials
-
Hyperlexia 0 trials
-
Hypermanganesemia with dystonia 2 0 trials
-
Lateral meningocele syndrome 0 trials
-
Lissencephaly spectrum disorders 0 trials
14 sub-types
- Baraitser-Winter cerebrofrontofacial syndrome 0 trials Sub-types →
- Warburg micro syndrome 0 trials Sub-types →
- X-linked lissencephaly with abnormal genitalia 0 trials
- Classic lissencephaly 0 trials Sub-types →
- Cobblestone lissencephaly 0 trials Sub-types →
- Craniotelencephalic dysplasia 0 trials
- Lissencephaly 10 0 trials
- Lissencephaly 7 with cerebellar hypoplasia 0 trials
- Lissencephaly 8 0 trials
- Lissencephaly spectrum disorder with complex brainstem malformation 0 trials Sub-types →
- Lissencephaly type 3 0 trials Sub-types →
- Lissencephaly with cerebellar hypoplasia 0 trials Sub-types →
- Massa casaer ceulemans syndrome 0 trials
- Microlissencephaly 0 trials Sub-types →
-
Major affective disorder 1 0 trials
-
Major affective disorder 2 0 trials
-
Major affective disorder 3 0 trials
-
Major affective disorder 4 0 trials
-
Major affective disorder 5 0 trials
-
Major affective disorder 7 0 trials
-
Major affective disorder 8 0 trials
-
Major affective disorder 9 0 trials
-
Myofibrillar myopathy 5 0 trials
-
Myopic macular degeneration 0 trials
-
Myosclerosis 0 trials
-
Narcolepsy 3 0 trials
-
Narcolepsy 7 0 trials
-
2 sub-types
-
3 sub-types
- MYH7-related skeletal myopathy 0 trials
- Congenital myopathy 7A, myosin storage, autosomal dominant 0 trials
- Hyaline body myopathy 0 trials
-
2 sub-types
-
Neuroocular syndrome 0 trials
2 sub-types
-
Oculocerebrocutaneous syndrome 0 trials
-
Orofaciodigital syndrome type 6 0 trials
-
Parietal foramina 0 trials
3 sub-types
- Parietal foramina 1 0 trials
- Parietal foramina 2 0 trials
- Parietal foramina 3 0 trials
-
Parkinsonism with polyneuropathy 0 trials
-
Paroxysmal extreme pain disorder 0 trials
-
Periventricular nodular heterotopia 0 trials
8 sub-types
- Chromosome 5Q14.3 deletion syndrome, distal 0 trials
- Heterotopia, periventricular, X-linked dominant 0 trials
- Heterotopia, periventricular, associated with chromosome 5P anomalies 0 trials
- Periventricular heterotopia with microcephaly, autosomal recessive 0 trials
- Periventricular nodular heterotopia 6 0 trials
- Periventricular nodular heterotopia 7 0 trials
- Periventricular nodular heterotopia 8 0 trials
- Periventricular nodular heterotopia 9 0 trials
-
Phakomatosis pigmentokeratotica 0 trials
-
Prosopagnosia, hereditary 0 trials
-
Red color blindness 0 trials
-
Schizophrenia 15 0 trials
-
Schizophrenia 16 0 trials
-
Schizophrenia 19 0 trials
-
Typical nemaline myopathy 0 trials
6 sub-types
- Congenital myopathy 23 0 trials
- Congenital myopathy 2a, typical, autosomal dominant 0 trials
- Nemaline myopathy 10 0 trials
- Nemaline myopathy 2 0 trials
- Nemaline myopathy 7 0 trials
- Nemaline myopathy 9 0 trials
Most studied deeper sub-types
-
New combo aims to outperform keytruda in lung cancer
Disease control Stopped earlyThis phase 3 trial tests whether adding vibostolimab to pembrolizumab (Keytruda) helps people with PD-L1 positive metastatic non-small cell lung cancer live longer than pembrolizumab alone. Over 1,200 participants received either the combination or pembrolizumab every three weeks…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Tiny doses of avastin tested against laser for preemie eye disease
Disease control Stopped earlyThis study tested a low dose of the drug bevacizumab (Avastin) against standard laser treatment for retinopathy of prematurity, an eye disease that can blind premature infants. Sixteen babies with severe disease were enrolled. The goal was to see if the drug could control the dis…
Phase 3 • Sponsor: Jaeb Center for Health Research • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug combo aims to keep advanced breast cancer in check
Disease control Stopped earlyThis study tested whether a combination of olaparib (a targeted therapy) and pembrolizumab (an immunotherapy) works better than standard chemotherapy plus pembrolizumab for people with advanced triple-negative breast cancer that initially responded to chemo-immunotherapy. The tri…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New hope for High-Risk melanoma: combo therapy aims to prevent recurrence
Disease control Stopped earlyThis study tested whether adding vibostolimab to the standard immunotherapy pembrolizumab can better prevent melanoma from returning after surgery. About 1,600 people with high-risk stage II to IV melanoma took part. The goal was to see if the combination keeps cancer away longer…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Spinal injection drug targets genetic cause of ALS and dementia
Disease control Stopped earlyResearchers are testing repeated doses of an experimental drug called WVE-004 in adults who have ALS, frontotemporal dementia, or both, linked to a mutation in the C9orf72 gene. Participants receive the drug by spinal injection every 12 weeks for up to 96 weeks. The study tracks …
Phase 1/2 • Sponsor: Wave Life Sciences USA, Inc. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Seizure drug safety trial halted early for dravet and LGS patients
Disease control Stopped earlyThis study looked at the long-term safety of soticlestat when added to standard seizure medicines for people with Dravet syndrome or Lennox-Gastaut syndrome. It included 352 children and adults who had already been in earlier studies. The trial was terminated early, so results ar…
Phase 3 • Sponsor: Takeda • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a new drug tame seizures in two severe epilepsy syndromes?
Disease control Stopped earlyThis phase 3 trial tests whether soticlestat can reduce seizures in people with Dravet syndrome or Lennox-Gastaut syndrome who have already used fenfluramine. Participants take soticlestat as tablets or mini-tablets, and researchers measure changes in seizure frequency over the f…
Phase 3 • Sponsor: Takeda • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New drug shows promise for Tough-to-Treat seizures in kids
Disease control Stopped earlyThis study looked at the long-term safety of soticlestat, an experimental drug, in children and adults with severe forms of epilepsy like Dravet syndrome and Lennox-Gastaut syndrome. Participants took soticlestat twice a day along with their usual seizure medicines. The study was…
Phase 2 • Sponsor: Takeda • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Promising combo therapy for incurable liver cancer shows potential in phase 3 trial
Disease control Stopped earlyThis study tested whether adding two drugs (lenvatinib and pembrolizumab) to a standard liver cancer treatment called TACE helps people with liver cancer that cannot be removed by surgery. About 479 participants received either the drug combo plus TACE or TACE alone. The goal was…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can an antiviral drug protect hearing in infants with congenital CMV?
Disease control Stopped earlyThis trial tests whether the antiviral drug valganciclovir can improve hearing and language outcomes in infants who have hearing loss due to congenital cytomegalovirus (CMV) infection. Infants aged 1 to 12 months with confirmed sensorineural hearing loss will receive either valga…
Phase 2 • Sponsor: Albert Park • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Halted gene therapy study raises questions for AMN patients
Disease control Stopped earlyThis early-stage trial tested a gene therapy called SBT101 for adrenomyeloneuropathy (AMN), a rare nerve disease that causes walking difficulties. Eight adults received either the therapy or a sham procedure. The study was terminated early, so we have limited data on safety and e…
Phase 1/2 • Sponsor: SwanBio Therapeutics, Inc. • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Immune cells take on nerve tumors: new trial launches
Disease control Stopped earlyThis early-stage trial is testing whether specially engineered immune cells (called CAR-T and CTL cells) and a dendritic cell vaccine can safely treat people with neurofibromatosis or schwannomatosis, conditions that cause nerve tumors. The study will enroll 100 participants aged…
Phase 1/2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New drug cocktail aims to extend life in advanced esophageal cancer
Disease control Stopped earlyThis study tests whether adding lenvatinib to pembrolizumab and chemotherapy helps people with metastatic esophageal cancer live longer. About 864 participants receive either the new three-drug combo or standard care. The goal is to improve overall survival, but this is not a cur…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Experimental drug REC-2282 targets NF2 brain tumors in early trial
Disease control Stopped earlyThis study tested a drug called REC-2282 in people aged 12 and older with progressive meningiomas (brain tumors) linked to NF2 gene mutations. Participants took the drug or a placebo three times a week in cycles. The goal was to see if the drug could slow tumor growth. The trial …
Phase 2/3 • Sponsor: Recursion Pharmaceuticals Inc. • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New nasal spray aims to curb relentless hunger in rare genetic disorder
Disease control Stopped earlyThis study tests the long-term safety of a nasal spray called carbetocin for people with Prader-Willi syndrome who experience severe, constant hunger (hyperphagia). About 160 participants who completed a previous study will receive the spray three times daily. The goal is to see …
Phase 3 • Sponsor: ACADIA Pharmaceuticals Inc. • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New eye injection targets Blindness-Causing lesions
Disease control Stopped earlyThis early-stage study tests the safety of an experimental drug called RO7669330, given as an injection into the eye, for people with geographic atrophy (GA) due to age-related macular degeneration (AMD). The study involves 27 participants and will monitor side effects and eye he…
Phase 1 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Virtual cues on a treadmill: a new hope for Parkinson's falls?
Disease control Stopped earlyThis trial tests whether adding augmented reality (AR) to treadmill training can help people with Parkinson's disease who have trouble walking and are at risk of falling. Participants will be randomly assigned to one of three groups: treadmill training with AR, treadmill training…
Sponsor: Klinik Valens • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug combo shows promise for Hard-to-Treat lymphomas
Disease control Stopped earlyThis study tested a combination of two drugs, favezelimab and pembrolizumab, in 137 people with certain blood cancers like Hodgkin lymphoma and B-cell lymphoma. The goal was to see if the combination was safe and could shrink tumors. The study also looked at each drug alone in so…
Phase 1/2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Could a gel cut down on skin cancer surgeries? new trial investigates
Disease control Stopped earlyThis trial tests a gel called patidegib applied to the face twice daily for 9 months in people who develop many basal cell carcinomas (a common skin cancer) but do not have Gorlin syndrome. The goal is to see if the gel reduces the number of new skin cancers that would normally r…
Phase 2 • Sponsor: Sol-Gel Technologies, Ltd. • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Light-Activated cream could slow growth of NF1 skin tumors
Disease control Stopped earlyThis trial tests whether a light-activated cream (Levulan Kerastick) followed by red light therapy can slow the growth of benign skin tumors called neurofibromas in people with neurofibromatosis type 1 (NF1). About 30 participants aged 14 and older with superficial tumors on the …
Phase 2 • Sponsor: Donald Basel • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Genetic clues could personalize breast cancer treatment
Disease control Stopped earlyThis study looks at genetic changes in postmenopausal women with a common type of advanced breast cancer (HR+ HER2-). Participants first receive ribociclib plus letrozole; those with a specific mutation (PIK3CA) may later switch to alpelisib plus fulvestrant. The goal is to track…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Experimental Friedreich's ataxia drug tested in kids – but trial halted early
Disease control Stopped earlyThis early-stage trial tested a drug called nomlabofusp (CTI-1601) in 18 adolescents and children with Friedreich's ataxia, a rare genetic disease that affects movement and coordination. The goal was to check safety and how the body processes the drug. However, the study was term…
Phase 1 • Sponsor: Larimar Therapeutics, Inc. • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Real-World study tracks Selumetinib's impact on NF1 tumors in children
Disease control Stopped earlyThis study observes children aged 3 to 18 with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas and are starting treatment with selumetinib. Researchers will track how well the drug shrinks or stabilizes tumors, how long patients stay on tre…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New hope for rare hunger disorder: drug shows promise in Long-Term trial
Disease control Stopped earlyThis study tests whether ARD-101 can safely reduce extreme hunger and food-related behaviors in people with Prader-Willi syndrome over 12 months. About 90 participants who completed a prior study will take the drug daily and visit the clinic regularly. The goal is to improve qual…
Phase 3 • Sponsor: Aardvark Therapeutics, Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Could a common blood pressure drug shrink kidney tumors?
Disease control Stopped earlyThis pilot study tested whether propranolol, a beta-blocker, could shrink or stabilize kidney angiomyolipomas in people with tuberous sclerosis. Only 2 participants were enrolled before the trial was terminated, so the results are very limited. The goal was to find a less invasiv…
Phase 2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Gene therapy trial for rare childhood epilepsy halted after just one patient
Disease control Stopped earlyThis trial tested a single dose of CAP-002 gene therapy in children aged 18 months to 8 years with STXBP1 encephalopathy, a rare genetic brain disorder causing seizures and developmental delays. The study aimed to check safety and whether it could reduce seizures and improve skil…
Phase 1/2 • Sponsor: Capsida Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Experimental cancer drug trial halted early
Disease control Stopped earlyThis early-stage study tested a new drug called PF-07265807 in people with advanced or metastatic solid tumors that had spread. The main goals were to find a safe dose and check for side effects. The trial was terminated early, so results are limited.
Phase 1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Experimental cancer drug study halted early
Disease control Stopped earlyThis early-stage study tested a new drug called PF-07284892, alone or with other medicines, in people with advanced solid tumors that had specific genetic changes. The goal was to find the safest dose and check for side effects. The study was stopped early, so results are limited…
Phase 1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New pill for rheumatoid arthritis shows promise in early trial
Disease control Stopped earlyThis phase 2 study tested an experimental oral drug called BGB-45035 in 49 adults with moderate to severe rheumatoid arthritis who had not responded well to standard treatments. Participants received either the drug or a placebo to see if it could reduce joint pain and swelling. …
Phase 2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
Promising seizure drug study halted early
Disease control Stopped earlyThis study looked at the long-term safety of the drug NBI-921352 for people with a rare genetic seizure disorder called SCN8A-DEE. It was an extension of an earlier study, and participants took the drug alongside their usual seizure medications. The study was stopped early and on…
Phase 2 • Sponsor: Neurocrine Biosciences • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Can a daily injection reshape bodies of HIV patients?
Disease control Stopped earlyThis study looked at whether tesamorelin (Egrifta), a daily injection that boosts growth hormone, can improve body composition in people with HIV who have excess belly fat (lipodystrophy). Six participants received the drug for up to 12 months, with researchers measuring liver fa…
Phase 4 • Sponsor: Columbia University • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Anti-Inflammatory drug studied for PANDAS-Related OCD in kids
Disease control Stopped earlyThis study tested the anti-inflammatory drug naproxen sodium for treating obsessive-compulsive symptoms in children aged 6-15 with PANDAS, a condition linked to strep infections. The trial was double-blind and placebo-controlled, but it was terminated early after enrolling only 2…
Phase 4 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Warming blankets and fluids tested to prevent hypothermia in C-Section births
Disease control Stopped earlyThis study tested different warming methods—like forced air blankets and warmed IV fluids—to prevent hypothermia in women having planned C-sections. Only 16 women participated before the trial was stopped early. The goal was to see which method best keeps mother and baby warm and…
Sponsor: The University of Texas Health Science Center, Houston • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New cocktail of cancer drugs tested in desperate cases
Disease control Stopped earlyThis early-phase trial tested combinations of the drugs bevacizumab and temsirolimus, sometimes with valproic acid or cetuximab, in 154 people with advanced cancers or certain non-cancerous but progressive diseases. The main goal was to find safe doses and look for any signs that…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New prostate cancer combo trial ends early
Disease control Stopped earlyThis study tested a new drug called exicorilant (CORT125281) combined with enzalutamide in men with metastatic castration-resistant prostate cancer. The goal was to find a safe dose and check for side effects. The trial was terminated early, so results are limited. It involved 39…
Phase 1/2 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Continued EryDex treatment studied in rare neurological disorder
Disease control Stopped earlyThis study offered continued treatment with EryDex to 101 people with ataxia telangiectasia (A-T) who had finished a previous trial. The main goal was to monitor safety, including side effects and serious events. The study was terminated early, and it did not aim to cure the dise…
Phase 3 • Sponsor: Quince Therapeutics S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Could a repurposed drug tame seizures in adult dravet patients?
Disease control Stopped earlyThis study tested the drug fenfluramine (FINTEPLA) in adults with Dravet syndrome whose seizures were not controlled by other medications. The trial was open-label and added fenfluramine to existing treatments. It aimed to see if the drug could reduce monthly seizures by at least…
Phase 3 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Experimental Parkinson's drug talineuren put to early safety test
Disease control Stopped earlyThis early-stage trial tested the safety of an intravenous drug called talineuren (liposomal GM1) in 22 people with Parkinson's disease. The study was open-label and designed to find a safe dose, but it was terminated before completion. No conclusions about effectiveness can be d…
Phase 1 • Sponsor: InnoMedica Schweiz AG • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Hope dashed: drug trial for Post-COVID racing heart stopped early
Disease control Stopped earlyThis study tested a drug called IgPro20 (HIZENTRA) to see if it could help people with post-COVID POTS, a condition that causes a rapid heart rate and dizziness when standing. The trial was stopped early after enrolling only 16 adults. The goal was to see if the drug could reduce…
Phase 3 • Sponsor: CSL Behring • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Experimental drug TPN-101 tested in rare childhood brain disease
Disease control Stopped earlyThis study tested a drug called TPN-101 (censavudine) in people with Aicardi-Goutières syndrome, a rare genetic disorder that causes severe brain inflammation. The trial enrolled only 4 participants and aimed to see if the drug could reduce immune system overactivity and check fo…
Phase 2 • Sponsor: Transposon Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Parkinson's drug trial halted: what we learned from UCB0599
Disease control Stopped earlyThis study looked at whether taking UCB0599 early or later could slow brain changes in people with Parkinson's disease. It involved 428 adults who had already completed an earlier study. The trial was stopped early, but researchers measured brain scans and medication use over 18 …
Phase 2 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
DMD drug tested in wheelchair users – but trial stops early
Disease control Stopped earlyThis study tested the safety of golodirsen (Vyondys 53) in boys and men with Duchenne muscular dystrophy who can no longer walk. Only 2 people took part before the trial was stopped early. Participants received weekly IV infusions for up to 96 weeks, with extra follow-up. The goa…
Phase 4 • Sponsor: Rare Disease Research, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New drug aims to tame hard-to-control seizures in rare mitochondrial disorders
Disease control Stopped earlyThis study tested a drug called vatiquinone in 68 people with mitochondrial disease and epilepsy that doesn't respond to standard treatments. Participants were randomly assigned to receive either vatiquinone or a placebo for 24 weeks to see if the drug could reduce the number of …
Phase 2/3 • Sponsor: PTC Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Epilepsy drug study halted early: BHV-7000 shows limited promise
Disease control Stopped earlyThis study tested whether BHV-7000, taken alongside other medications, could reduce generalized tonic-clonic seizures in people with idiopathic generalized epilepsy. The trial was terminated early and enrolled only 27 adults aged 18-75. The main goal was to see how long it took f…
Phase 2/3 • Sponsor: Biohaven Therapeutics Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Experimental drug shows promise for rare genetic disorder
Disease control Stopped earlyThis Phase II trial tested a drug called N-Acetyl-L-Leucine (IB1001) in 17 people with Ataxia-Telangiectasia, a rare genetic disease that affects movement and immunity. The study aimed to see if the drug could improve symptoms and slow the disease over time. The trial was termina…
Phase 2 • Sponsor: IntraBio Inc • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Experimental kidney cancer drug trial halted early
Disease control Stopped earlyThis early-stage trial tested a new drug called DFF332, which targets a protein (HIF2α) that helps some cancers grow. The study included 40 adults with advanced clear cell renal cell carcinoma or other cancers with specific gene changes. DFF332 was tested alone and in combination…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
OCD drug trial halted early: what happened with troriluzole?
Disease control Stopped earlyThis study looked at the long-term safety of a drug called troriluzole for people with obsessive-compulsive disorder (OCD) who hadn't improved enough with standard treatments. The trial planned to enroll 772 participants but was terminated early. The main goal was to check for si…
Phase 3 • Sponsor: Biohaven Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Experimental cancer drug tested in rare tumors, but trial stopped early
Disease control Stopped earlyThis phase 2 trial tested the drug guadecitabine (SGI-110) in people aged 12 and older with rare cancers like wild-type GIST, pheochromocytoma, paraganglioma, and HLRCC-related kidney cancer that had not responded to other treatments. Participants received daily injections for 5 …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Virus therapy fails to advance in colorectal cancer trial
Disease control Stopped earlyThis study tested a new approach using a virus that attacks cancer cells (oncolytic immunotherapy) along with two standard drugs (atezolizumab and bevacizumab) in people with advanced colorectal cancer that had stopped responding to other treatments. The trial was stopped early a…
Phase 2 • Sponsor: Replimune, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Experimental vaccine combo for rare adrenal cancers shows early promise but trial halted
Disease control Stopped earlyThis early-phase trial tested a new therapeutic vaccine (EO2401) combined with the immunotherapy drug nivolumab in 70 people with advanced adrenocortical carcinoma or malignant pheochromocytoma/paraganglioma. The goal was to see if the combination is safe and can shrink tumors or…
Phase 1/2 • Sponsor: Enterome • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Gene therapy shot for dry AMD shows promise in early trial
Disease control Stopped earlyThis study tested a single injection of a gene therapy called GT005 in 98 people with geographic atrophy, an advanced form of dry age-related macular degeneration that causes vision loss. The goal was to see if the treatment could slow the growth of damaged areas in the eye and c…
Phase 2 • Sponsor: Gyroscope Therapeutics Limited • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Hope fades: trial of Tay-Sachs drug venglustat terminated early
Disease control Stopped earlyThis Phase 3 trial tested an oral drug called venglustat in 75 adults and children with late-onset Tay-Sachs or Sandhoff disease, rare genetic disorders that cause progressive nerve damage. The drug aimed to lower toxic fat buildup in the brain and slow disease worsening. However…
Phase 3 • Sponsor: Genzyme, a Sanofi Company • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Gene therapy shot for dry AMD shows promise but trial halted early
Disease control Stopped earlyThis study tested a single injection of GT005, a gene therapy, in 255 people with geographic atrophy from dry age-related macular degeneration. The goal was to see if it could slow the growth of blind spots in the eye. The trial was terminated early, so we have less data than hop…
Phase 2 • Sponsor: Gyroscope Therapeutics Limited • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Experimental gene injection targets dry AMD
Disease control Stopped earlyThis early-stage trial tested a gene therapy called GT005 for dry age-related macular degeneration (AMD), a leading cause of vision loss. The therapy delivers a working gene to the retina via a single injection. The study enrolled 56 people and focused on safety and dosing, but w…
Phase 1/2 • Sponsor: Gyroscope Therapeutics Limited • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Gene therapy zolgensma tested in kids with SMA who can sit but not stand
Disease control Stopped earlyThis phase 1 trial tested a gene therapy called AVXS-101 (Zolgensma) in 32 children with spinal muscular atrophy (SMA) who could sit but not stand or walk. The therapy delivers a working SMN gene via a spinal injection to help improve muscle function. The study focused on safety …
Phase 1 • Sponsor: Novartis Gene Therapies • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
Neurodegenerative drug study ends early after only 17 participants
Disease control Stopped earlyThis study was designed to let people who had already taken latozinemab in an earlier study continue receiving the drug. Only 17 people took part, and the study was stopped early. The goal was to track safety and how long people stayed on treatment, not to test if the drug could …
Phase 3 • Sponsor: Alector Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Hope for genetic dementia: AL001 trial ends early
Disease control Stopped earlyThis phase 3 study tested a drug called AL001 in 119 people who carry a mutation in the progranulin gene, putting them at high risk for or already diagnosed with frontotemporal dementia. The goal was to see if AL001 could slow the worsening of memory, behavior, and language probl…
Phase 3 • Sponsor: Alector Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Experimental gene therapy for rare muscle disease shows early promise but study halted
Disease control Stopped earlyThis study tested a gene therapy called SRP-9003 for people with limb-girdle muscular dystrophy type 2E (LGMD2E), a rare genetic disease that causes muscle weakness. The treatment aimed to deliver a working gene to muscle cells to help them produce a missing protein. Only 6 peopl…
Phase 1/2 • Sponsor: Sarepta Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Experimental gene therapy aims to halt vision loss in rare blindness
Disease control Stopped earlyThis study tested a gene therapy for retinitis pigmentosa, an inherited eye disease that causes gradual vision loss. The treatment involved injecting a corrected gene under the retina in one eye. The trial included 19 people aged 13 and older with a specific genetic defect. The m…
Phase 1/2 • Sponsor: eyeDNA Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Huntington's drug safety study halted early
Disease control Stopped earlyThis study aimed to see if the drug SAGE-718 is safe for people with Huntington's disease when taken over a long period. It was an open-label study, meaning everyone knew they were getting the drug. The study was terminated early, so results are limited.
Phase 3 • Sponsor: Supernus Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
ALS drug trial halted: safety data sought from 54 patients
Disease control Stopped earlyThis study tested a new drug called VRG50635 in 54 people with ALS (Lou Gehrig's disease). The main goal was to check if the drug is safe and how the body processes it. The trial was stopped early, but researchers were looking for side effects and changes in disease progression.
Phase 1 • Sponsor: Verge Genomics • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Eye injections tested to save sight in rare coats disease
Disease control Stopped earlyThis study tested whether anti-VEGF injections into the eye could help treat Coats disease, a rare condition that causes abnormal blood vessels and fluid buildup in the retina, potentially leading to blindness. The trial included 18 people with early-stage Coats disease who had n…
Phase 3 • Sponsor: Fondation Ophtalmologique Adolphe de Rothschild • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Immunotherapy plus radiation for early lung cancer: trial halted early
Disease control Stopped earlyThis phase 3 trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to precise, high-dose radiation (SBRT) could help prevent early-stage non-small cell lung cancer from returning. The study enrolled 448 people with stage I or II lung cancer who could not hav…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Experimental drug AR-42 tested on brain tumors – early results uncertain
Disease control Stopped earlyThis early-phase trial tested the drug AR-42 in 7 adults with vestibular schwannoma or meningioma brain tumors who were already scheduled for surgery. Participants took AR-42 pills for about 3 weeks before their operation. The main goal was to see if the drug could lower a protei…
Early phase 1 • Sponsor: Massachusetts Eye and Ear Infirmary • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Experimental drug losmapimod tested in rare muscle disease – early hopes, but trial cut short
Disease control Stopped earlyThis study tested an experimental drug called losmapimod in 14 adults with FSHD1, a rare genetic condition that causes progressive muscle weakness. The main goal was to check safety and tolerability, and to see if the drug affects certain biological markers. The trial was termina…
Phase 2 • Sponsor: Fulcrum Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New drug trial for duchenne MD halted early – what we know
Disease control Stopped earlyThis phase 2 study tested a drug called PGN-EDO51 in 7 people with Duchenne muscular dystrophy whose genetic mutation can be corrected by skipping exon 51. The drug was given by IV infusion to see if it is safe and tolerable. The trial was terminated, so results are limited.
Phase 2 • Sponsor: PepGen Inc • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Promising cream for rare skin condition falls short in early trial
Disease control Stopped earlyThis study tested a sirolimus cream (0.2% and 0.4%) applied daily for 12 weeks to treat facial angiofibromas in children aged 2-21 with tuberous sclerosis complex. The goal was to see if the cream could safely reduce the size and redness of these skin growths. The trial was termi…
Phase 2 • Sponsor: Aucta Pharmaceuticals, Inc • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Experimental gene therapy for DMD hits antibody barrier – study halted
Disease control Stopped earlyThis study tested a gene therapy (delandistrogene moxeparvovec) combined with a drug called imlifidase to see if it could safely deliver the therapy to boys with Duchenne muscular dystrophy who had antibodies that might block the treatment. Only 5 participants were planned, but t…
Phase 1 • Sponsor: Sarepta Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New surgical trick may fix stubborn eye holes
Disease control Stopped earlyThis study tested a new surgical technique for macular holes that remained open after standard treatment. The procedure involves moving a thin membrane from the eye to cover the hole. Only 16 people were enrolled, and the study was stopped early, so we don't yet know if this appr…
Sponsor: Groupe Hospitalier de la Region de Mulhouse et Sud Alsace • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
FSHD drug trial halted midway: what happened?
Disease control Stopped earlyThis study tested a drug called losmapimod for people with a rare muscle-weakening disease called FSHD. The goal was to see if the drug could slow muscle loss and improve arm function over 48 weeks. About 260 adults with FSHD were randomly assigned to receive either losmapimod or…
Phase 3 • Sponsor: Fulcrum Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Experimental cell therapy targets deadly childhood brain cancer
Disease control Stopped earlyThis early-phase trial tested a new immunotherapy approach for children with DIPG, a rare and aggressive brain stem tumor. After standard radiation and chemotherapy, patients received special vaccines and immune cells designed to attack the tumor. The study was small (11 particip…
Phase 1 • Sponsor: University of Florida • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Parkinson's drug trial halted early: what happened?
Disease control Stopped earlyThis study tested an experimental drug called VENT-02 in 29 people with mild to moderate Parkinson's disease. The drug aims to reduce brain inflammation by blocking a protein called NLRP3. The trial was terminated early, so we don't have clear results on whether it helps symptoms…
Phase 1/2 • Sponsor: Ventus Therapeutics U.S., Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Experimental drug for Post-COVID POTS study halted early
Disease control Stopped earlyThis study looked at the long-term safety of efgartigimod in adults with post-COVID postural orthostatic tachycardia syndrome (POTS), a condition causing rapid heart rate and dizziness upon standing. The trial was an open-label extension for people who completed a previous study.…
Phase 2 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Experimental gene therapy targets duchenne MD in young boys
Disease control Stopped earlyThis Phase 2 trial tested a single dose of gene therapy (fordadistrogene movaparvovec) in 10 boys with early-stage Duchenne muscular dystrophy. The goal was to check safety and whether the therapy could help muscles produce a mini-dystrophin protein. The study was terminated earl…
Phase 2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Gene therapy for duchenne muscular dystrophy under Long-Term watch
Disease control Stopped earlyThis study follows 7 people with Duchenne muscular dystrophy who previously received an experimental gene therapy called fordadistrogene movaparvovec. Researchers will monitor them for 10 years to check for side effects and see if the treatment continues to help with movement. Th…
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Promising epilepsy drug trial halted early – what we know
Disease control Stopped earlyThis study tested an experimental drug called NBI-921352 in people aged 2 to 21 with a rare, severe form of epilepsy caused by a change in the SCN8A gene. The goal was to see if adding this drug to their current seizure medicines could reduce how often they had seizures. The tria…
Phase 2 • Sponsor: Neurocrine Biosciences • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Dravet syndrome drug trial halted early: did lorcaserin help?
Disease control Stopped earlyThis study tested whether lorcaserin, when added to current medications, could reduce convulsive seizures in people with Dravet syndrome, a severe form of epilepsy. The trial planned to enroll about 22 participants aged 2 and older, but it was terminated early. The main goal was …
Phase 3 • Sponsor: Eisai Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Experimental cancer cocktails show promise, but study halted early
Disease control Stopped earlyThis early-stage trial tested two drug combinations—TNO155 plus spartalizumab or ribociclib—in 122 adults with advanced solid tumors like lung, head and neck, and colorectal cancers. The goal was to check safety and see if the drugs could slow cancer growth. The study was termina…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Experimental drug losmapimod tested for rare muscle disease
Disease control Stopped earlyThis phase 2 trial tested the drug losmapimod in 76 adults with FSHD, a genetic condition that causes progressive muscle weakness. Participants took either losmapimod or a placebo for 48 weeks to see if the drug was safe and could help control the disease. The study was terminate…
Phase 2 • Sponsor: Fulcrum Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Experimental seizure drug tested in rare genetic disorder
Disease control Stopped earlyThis phase 3 study tested the drug ganaxolone as an add-on treatment for seizures in children and adults with tuberous sclerosis complex (TSC). The trial was open-label, meaning everyone received the drug, and it included 117 people who had previously been in related studies. The…
Phase 3 • Sponsor: Marinus Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Experimental drug zavesca tested for rare fatal brain diseases in infants
Disease control Stopped earlyThis phase 3 trial tested the drug miglustat (Zavesca) in 30 infants with Sandhoff or Tay-Sachs diseases, rare genetic disorders that destroy nerve cells. The goal was to see if the drug could reduce hospitalizations, seizures, and feeding problems while improving motor function.…
Phase 3 • Sponsor: Tehran University of Medical Sciences • Aim: Disease control
Last updated Jun 26, 2026 17:51 UTC
-
Gene therapy trial for duchenne MD halted early – what we know
Disease control Stopped earlyThis early-stage trial tested a single infusion of gene therapy (PF-06939926) in 23 people with Duchenne muscular dystrophy, both those who could still walk and those who could not. The main goal was to check safety and tolerability, while also measuring dystrophin protein levels…
Phase 1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 26, 2026 17:12 UTC
-
Eye drug trial halted: could danicopan still slow blind spots?
Disease control Stopped earlyThis Phase 2 study tested an oral drug called danicopan in 365 people with geographic atrophy, an advanced form of dry age-related macular degeneration that causes blind spots. Participants took different doses of danicopan or a placebo for up to 104 weeks to see if it could slow…
Phase 2 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 26, 2026 14:21 UTC
-
Can plasma exchange clear the way for gene therapy in duchenne?
Disease control Stopped earlyThis early study tested whether a blood-cleaning procedure called plasmapheresis could allow boys with Duchenne muscular dystrophy who have antibodies against the gene therapy carrier to still receive the treatment. Only 3 boys were enrolled before the study was stopped early. Th…
Phase 1 • Sponsor: Sarepta Therapeutics, Inc. • Aim: Disease control
Last updated Jun 26, 2026 14:20 UTC
-
Experimental gene therapy for rare muscle disease tested in just 2 people
Disease control Stopped earlyThis was a very early (Phase 1) study testing a gene therapy called SRP-6004 for people with limb girdle muscular dystrophy type 2B/R2, a rare muscle-weakening disease. The goal was to see if a single IV infusion of the therapy is safe and can help the body produce a missing prot…
Phase 1 • Sponsor: Sarepta Therapeutics, Inc. • Aim: Disease control
Last updated Jun 26, 2026 14:20 UTC
-
Experimental gene therapy tested for rare muscular dystrophy
Disease control Stopped earlyThis early-stage trial tested a gene therapy called SRP-9004 in just 4 people with limb girdle muscular dystrophy type 2D/R3, a rare muscle-weakening disease. The main goal was to check safety, not effectiveness. The study was terminated early, so results are limited.
Phase 1 • Sponsor: Sarepta Therapeutics, Inc. • Aim: Disease control
Last updated Jun 26, 2026 13:47 UTC
-
Experimental gene therapy targets Tay-Sachs and sandhoff in kids
Disease control Stopped earlyThis early-stage trial tested a gene therapy called AXO-AAV-GM2 in children with Tay-Sachs or Sandhoff disease, rare and fatal genetic brain disorders. The therapy delivers healthy genes directly into the brain and spinal fluid to try to restore a missing enzyme. The study was te…
Phase 1 • Sponsor: Terence Flotte • Aim: Disease control
Last updated Jun 26, 2026 13:03 UTC
-
New PET tracer aims to spot Parkinson's protein in living brains
Diagnosis Stopped earlyThis early-phase study tests a new imaging drug called [18F]MK-0947 that works with PET scans to show where a protein called α-synuclein builds up in the brain—a hallmark of Parkinson's disease. Researchers will check safety and how well the tracer works in 22 adults (some with P…
Early phase 1 • Sponsor: Invicro • Aim: Diagnosis
Last updated Jul 29, 2026 00:00 UTC
-
New oral test could replace painful insulin injections for hormone diagnosis
Diagnosis Stopped earlyThis study tested a new oral drink (GS3-007a) to diagnose adult growth hormone deficiency (AGHD). It compared the drink to the standard insulin tolerance test in 120 adults suspected of having AGHD and healthy volunteers. The goal was to see if the oral test works as well as the …
Phase 2 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Diagnosis
Last updated Jun 27, 2026 12:37 UTC
-
Neck-Worn swallow detector fails key test
Diagnosis Stopped earlyThis study tested a wearable device that sits on the neck to detect swallowing problems in people with conditions like stroke, Parkinson's, multiple sclerosis, Alzheimer's, or dementia. The device was compared to a standard X-ray test. Unfortunately, the device did not meet the a…
Sponsor: Société des Produits Nestlé (SPN) • Aim: Diagnosis
Last updated Jun 27, 2026 08:05 UTC
-
Corn could be key to saving your eyesight
Prevention Stopped earlyThis study looked at whether eating corn rich in zeaxanthin (a natural pigment) could increase the density of the macular pigment in the eye, which may help prevent age-related macular degeneration (AMD), a leading cause of blindness. Nine healthy volunteers aged 20-35 ate a dail…
Sponsor: University Hospital, Bordeaux • Aim: Prevention
Last updated Jun 27, 2026 12:37 UTC
-
Does mixing numbing agent into steroid shots ease hand pain?
Symptom relief Stopped earlyDoctors often treat trigger finger, de Quervain's tenosynovitis, and carpal tunnel syndrome with steroid injections. Some mix in a local anaesthetic to reduce pain after the shot, while others do not. This trial compares pain levels in adults who receive a steroid injection with …
Phase 3 • Sponsor: University Hospital Plymouth NHS Trust • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
Could a High-Fat diet boost brain health in early Alzheimer's?
Symptom relief Stopped earlyThis study looks at whether a ketogenic diet (high-fat, low-carb) is practical and safe for people with early-stage Alzheimer's disease over one year. The diet may provide an alternative energy source for the brain and reduce inflammation. Researchers will track diet adherence, b…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Symptom relief
Last updated Sep 12, 2026 00:00 UTC
-
Can a Quit-Smoking program built for transgender adults help them stop?
Symptom relief Stopped earlyTransgender and gender diverse adults smoke at higher rates than the general population, and stigma, discrimination, anxiety, and depression may make quitting harder. Researchers at Massachusetts General Hospital are adapting an existing smoking cessation program called QUIT, whi…
Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
Can a breathing gadget calm anxious teens?
Symptom relief Stopped earlyThis study tests whether a biofeedback breathing system called Freespira can reduce anxiety and panic symptoms in young people aged 9 to 17. Over 8 weeks, one group uses the device while a control group waits. The goal is to see if the device helps lower anxiety scores on a stand…
Sponsor: Johns Hopkins University • Aim: Symptom relief
Last updated Sep 05, 2026 00:00 UTC
-
Dementia agitation drug trial halted after just 5 patients
Symptom relief Stopped earlyThis study tested a fast-dissolving film (BXCL501) placed under the tongue to quickly reduce severe agitation in older adults with dementia. The trial aimed to enroll many participants but was stopped early after only 5 people joined. Because it ended so soon, we cannot draw reli…
Phase 2 • Sponsor: BioXcel Therapeutics Inc • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
Can a synthetic cannabinoid calm agitation in frontotemporal dementia?
Symptom relief Stopped earlyThis phase 2 trial tests whether nabilone, a synthetic cannabinoid, can reduce agitation in people with frontotemporal dementia (FTD). Participants receive both nabilone and a placebo in random order to compare effects. The study includes adults with behavioral variant FTD or pri…
Phase 2 • Sponsor: Simon Ducharme, MD • Aim: Symptom relief
Last updated Jul 30, 2026 00:00 UTC
-
Tiny incision, big relief? ultrasound procedure challenges carpal tunnel surgery
Symptom relief Stopped earlyThis study compared a new, minimally invasive ultrasound-guided procedure to standard surgery for carpal tunnel syndrome. The goal was to see if the new technique could provide similar relief with a smaller incision and faster recovery. Only 7 people were enrolled before the stud…
Sponsor: GCS Ramsay Santé pour l'Enseignement et la Recherche • Aim: Symptom relief
Last updated Jul 18, 2026 00:00 UTC
-
Hope for rare hunger disorder: new drug enters final testing phase
Symptom relief Stopped earlyThis phase 3 trial tests whether ARD-101 can reduce the intense, constant hunger (hyperphagia) seen in Prader-Willi syndrome. About 90 participants will take either ARD-101 or a placebo daily for 12 weeks. Caregivers will track changes in hunger-related behaviors using a standard…
Phase 3 • Sponsor: Aardvark Therapeutics, Inc. • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
Nerve block or antidepressant? study tests two migraine treatments Head-to-Head
Symptom relief Stopped earlyThis study compares two treatments for transformed migraine (chronic daily headache): a sphenopalatine ganglion nerve block using lidocaine gel applied inside the nose, versus daily oral amitriptyline (Elavil), an antidepressant often used for migraine prevention. Ten adults aged…
Phase 4 • Sponsor: Rutgers, The State University of New Jersey • Aim: Symptom relief
Last updated Jun 27, 2026 14:03 UTC
-
Could a nerve pain drug and exercise ease long COVID fatigue?
Symptom relief Stopped earlyThis study tests whether the drug pregabalin, alone or with a rehabilitation program, can reduce chronic fatigue in people with post-COVID syndrome. Participants are adults aged 18 to 65 who had COVID-19 at least six months ago and still feel very tired. The trial compares four g…
Phase 2 • Sponsor: National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Parkinson's drug side effect targeted by antioxidant NAC – but trial stalls
Symptom relief Stopped earlyThis study tested whether N-acetylcysteine (NAC), an antioxidant, could help reduce impulse control disorders caused by Parkinson's medications. Only 14 people with mild-to-moderate symptoms were enrolled before the trial was stopped early. The goal was to see if 10 weeks of NAC …
Phase 3 • Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Symptom relief
Last updated Jun 27, 2026 13:07 UTC
-
Lavender scent tested to ease Women's pain and anxiety during procedure
Symptom relief Stopped earlyThis study tested whether smelling lavender essential oil before and during an office hysteroscopy (a procedure to look inside the uterus) could lower women's anxiety and pain. Twenty-two women were randomly assigned to inhale either lavender oil or distilled water (placebo). The…
Phase 2 • Sponsor: University of Florida • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
New radiation technique aims to calm tremors without surgery
Symptom relief Stopped earlyThis study tested a new way to treat hand tremors caused by essential tremor or Parkinson's disease using a linear accelerator, a common radiation machine. Instead of one large dose, the radiation was given in three smaller sessions to protect healthy brain tissue. The goal was t…
Phase 2 • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
New therapy targets memory doubts to curb OCD checking
Symptom relief Stopped earlyThis study tested a new, short therapy module for people with obsessive-compulsive disorder (OCD) who struggle with compulsive checking. The therapy focuses on fixing unhelpful beliefs about memory that drive the urge to check. Researchers aimed to see if this approach reduces ch…
Sponsor: University of Manitoba • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
Mindfulness app for anxiety in underserved groups fizzles out early
Symptom relief Stopped earlyThis study tested a smartphone app that teaches mindfulness meditation to help Black and Latino adults with anxiety during the COVID-19 pandemic. About 400 participants were assigned to one of two mindfulness programs or a waitlist. The trial was terminated early, so we don't hav…
Sponsor: University of North Carolina, Chapel Hill • Aim: Symptom relief
Last updated Jun 27, 2026 12:33 UTC
-
Experimental drug aims to curb disinhibition in dementia patients
Symptom relief Stopped earlyThis study tested a drug called AVP-786 to see if it could safely reduce disinhibition—impulsive or inappropriate behavior—in people with neurodegenerative disorders like Alzheimer's or frontotemporal dementia. The trial planned to include many participants but was terminated ear…
Phase 2 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC
-
Touchscreen device aims to give voice to dementia patients
Symptom relief Stopped earlyThis study tested a personalized touchscreen device (My PATI) to help people with Alzheimer's or related dementias communicate their care preferences. The goal was to improve quality of life for both patients and their caregivers. The study was terminated early, so results are li…
Sponsor: Florida International University • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC
-
Personalized exercise trial for chronic fatigue ends early
Symptom relief Stopped earlyThis study tested whether a personalized exercise program could reduce fatigue in people with chronic fatigue syndrome. About 101 participants were planned, but the trial was terminated early. The approach involved tailoring aerobic and resistance exercises based on weekly fatigu…
Sponsor: Centre Hospitalier Universitaire de Saint Etienne • Aim: Symptom relief
Last updated Jun 27, 2026 12:30 UTC
-
Brain zaps for pain and fatigue: a quick fix?
Symptom relief Stopped earlyThis study looked at whether a brief, noninvasive brain stimulation technique called tDCS could immediately reduce pain and improve function in people with fibromyalgia or chronic fatigue syndrome. About 20 participants received one session, and researchers measured changes in pa…
Sponsor: Hospital Donostia • Aim: Symptom relief
Last updated Jun 27, 2026 12:30 UTC
-
CBDV study for Prader-Willi syndrome halted early
Symptom relief Stopped earlyThis study tested whether a cannabis-derived compound called CBDV could safely reduce irritability in children and young adults with Prader-Willi syndrome. Only 6 people enrolled before the study was stopped early. The goal was to see if CBDV helped with mood and behavior problem…
Phase 2 • Sponsor: Eric Hollander • Aim: Symptom relief
Last updated Jun 27, 2026 12:30 UTC
-
Robot trainer aims to help Parkinson's patients walk better
Symptom relief Stopped earlyThis study tested a robotic device called the G-EO Gait Trainer to help people with Parkinson's disease improve their walking. The device supports the body and guides leg movements to make walking practice safer and more effective. The trial was terminated early, so only limited …
Sponsor: Indiana University • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
Can a blood injection boost carpal tunnel surgery results?
Symptom relief Stopped earlyThis study looked at whether adding platelet-rich plasma (PRP) to standard carpal tunnel release surgery helps people with severe carpal tunnel syndrome. The trial planned to enroll 15 adults with severe nerve damage. It compared surgery with PRP to surgery alone. The study was t…
Sponsor: Michael Fredericson, MD • Aim: Symptom relief
Last updated Jun 27, 2026 12:26 UTC
-
HIV-Positive Men's mental health study shuts down after just one participant
Symptom relief Stopped earlyThis study aimed to see if acceptance and commitment therapy (ACT), a type of talk therapy, could help HIV-positive men with mental health issues like stress and anxiety. Only one person enrolled before the study was stopped early. Because of this, no meaningful results were obta…
Sponsor: University of Alabama at Birmingham • Aim: Symptom relief
Last updated Jun 27, 2026 12:09 UTC
-
Mindfulness may ease anxiety for heart device patients
Symptom relief Stopped earlyThis study tested whether a mindfulness program (including meditation, body scans, and gentle yoga) could help people with implanted heart devices like ICDs or pacemakers feel less anxious, stressed, and depressed. The study planned to enroll 34 adults who had recently received s…
Sponsor: Chien Chih-Yin • Aim: Symptom relief
Last updated Jun 27, 2026 12:08 UTC
-
Walking poles tested for Parkinson's: a simple step forward?
Symptom relief Stopped earlyThis study looked at whether using walking poles during an 8-week independent walking program could improve walking and activity levels in people with Parkinson's disease. Eleven participants were assigned to walk with or without poles at least three times a week. The trial was t…
Sponsor: Pacific Northwest University of Health Sciences • Aim: Symptom relief
Last updated Jun 27, 2026 12:02 UTC
-
New drug aimed at treating apathy in dementia patients tested
Symptom relief Stopped earlyThis study tested a drug called CVL-871 to see if it is safe and can help reduce apathy (lack of motivation or interest) in people with dementia. The trial included 41 participants with mild to moderate dementia and clinically significant apathy. The main goal was to check for si…
Phase 2 • Sponsor: AbbVie • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Parkinson's sleep study halted early – what we know
Symptom relief Stopped earlyThis study looked at whether the drug safinamide (Xadago) could improve sleep quality in people with Parkinson's disease. Eleven participants took safinamide for 12 weeks while their sleep was measured. The trial was terminated early, so the results are not conclusive.
Phase 4 • Sponsor: Alain Kaelin • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Could a Head-Zap at home boost your brain?
Symptom relief Stopped earlyThis study tested whether a gentle, non-invasive brain stimulation technique (tDCS) done at home, along with computer-based brain games, could improve thinking and language skills in people with primary progressive aphasia, mild cognitive impairment, or dementia. Participants use…
Sponsor: Johns Hopkins University • Aim: Symptom relief
Last updated Jun 27, 2026 09:08 UTC
-
Parkinson's apathy drug trial stalls after just 8 patients
Symptom relief Stopped earlyThis study tested whether istradefylline, a drug already approved for motor symptoms in Parkinson's, could also improve apathy and motivation. Only 8 people enrolled before the trial was terminated early. The results are too limited to draw any conclusions.
Sponsor: Medical University of South Carolina • Aim: Symptom relief
Last updated Jun 27, 2026 09:01 UTC
-
Brain pacemaker tested for uncontrollable tics
Symptom relief Stopped earlyThis study tested whether deep brain stimulation (DBS) could help people with severe Tourette syndrome whose symptoms don't improve with medication. Researchers placed tiny electrodes in a part of the brain called the thalamus to try to calm abnormal signals that cause tics. Only…
Sponsor: Johns Hopkins University • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
Online therapy steps up against OCD in new study
Symptom relief Stopped earlyThis study tested whether a stepped-care approach using internet-based cognitive behavioral therapy (ICBT) works as well as group therapy or standard medical care for adults with obsessive-compulsive disorder (OCD). 46 adults in China received one of the three treatments for 6 we…
Sponsor: Shanghai Mental Health Center • Aim: Symptom relief
Last updated Jun 27, 2026 08:12 UTC
-
Can zapping two brain areas at once stop Parkinson's freezing?
Symptom relief Stopped earlyThis study tested whether a high-dose magnetic stimulation (TMS) targeting both motor and cognitive brain areas could better reduce freezing of gait in people with Parkinson's disease compared to standard low-dose stimulation of just the motor area. The trial planned to enroll 64…
Sponsor: Anhui Medical University • Aim: Symptom relief
Last updated Jun 27, 2026 07:58 UTC
-
Calm app tested on stressed doctors – but study cut short
Symptom relief Stopped earlyThis study looked at whether using the Calm meditation app could help medical residents and fellows at Banner University Medical Center Phoenix feel less stressed, anxious, or burned out during the COVID-19 pandemic. Only 7 people signed up, and the study was stopped early, so we…
Sponsor: University of Arizona • Aim: Symptom relief
Last updated Jun 27, 2026 07:56 UTC
-
CBD study for baby seizures halted early
Symptom relief Stopped earlyThis study tested a cannabidiol (CBD) oral solution in children under 2 years old with tuberous sclerosis complex, Dravet syndrome, or Lennox-Gastaut syndrome who had uncontrolled seizures. The goal was to see if CBD is safe and can reduce seizures. However, the study was termina…
Phase 3 • Sponsor: Jazz Pharmaceuticals • Aim: Symptom relief
Last updated Jun 27, 2026 07:56 UTC
-
Parkinson's inhaler trial halted after just 8 patients
Symptom relief Stopped earlyThis study tested an inhaled form of apomorphine (AZ-009) to quickly treat 'OFF' episodes in people with Parkinson's disease—times when symptoms like stiffness or trouble moving return between regular medication doses. The trial was planned for more participants but was terminate…
Phase 2 • Sponsor: Alexza Pharmaceuticals, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 07:55 UTC
-
Can personalized recall timing boost word learning in kids with DLD?
Knowledge-focused Stopped earlyThis study explores whether tailoring when children with developmental language disorder (DLD) practice recalling new words can improve their learning. Researchers compare a standard fixed schedule to an adaptive one that adjusts to each child's progress. Four- and five-year-olds…
Sponsor: Purdue University • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
Can genetics predict the worsening of geographic atrophy?
Knowledge-focused Stopped earlyThis study follows people with geographic atrophy, a severe form of age-related macular degeneration that causes blind spots, to see how their vision changes over time. Researchers will measure visual function, such as reading speed and sensitivity to light, and track the growth …
Sponsor: Hoffmann-La Roche • Aim: Knowledge-focused
Last updated Aug 28, 2026 00:00 UTC
-
Can a coordinated care team ease the aftermath of intensive care?
Knowledge-focused Stopped earlyThis pilot study tests a new approach to supporting people after a stay in the intensive care unit (ICU). Many ICU survivors face ongoing psychological and physical challenges, such as depression, anxiety, and disability. The intervention involves a case manager who coordinates a…
Sponsor: Region Stockholm • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Could a simple blood test track nerve damage? a study investigates NT-3 levels in neuropathy.
Knowledge-focused Stopped earlyThis study measures levels of a protein called NT-3 in the blood of people with peripheral neuropathy or Charcot-Marie-Tooth disease. Researchers will compare these levels with measures of muscle strength, mobility, and daily function. The goal is to see whether NT-3 levels corre…
Sponsor: Zarife Sahenk • Aim: Knowledge-focused
Last updated Jul 31, 2026 00:00 UTC
-
Brain scans reveal why dementia changes personality
Knowledge-focused Stopped earlyThis study investigates how Alzheimer's disease and frontotemporal dementia alter a person's sense of self and ability to understand others. Researchers will compare patients with healthy older adults using questionnaires and brain imaging. The goal is to link changes in self-awa…
Sponsor: University Hospital, Strasbourg, France • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC
-
Zapping the brain to unravel OCD in kids
Knowledge-focused Stopped earlyThis study looked at how a gentle brain stimulation technique called tDCS affects thinking and behavior in children aged 10-17 with obsessive-compulsive disorder (OCD). The goal was to understand brain processes linked to OCD, not to treat the condition. Only 6 participants were …
Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jul 12, 2026 00:00 UTC
-
Psychedelics rewire Brain's learning? yale study investigates
Knowledge-focused Stopped earlyThis observational study at Yale University is recruiting 200 people who are already taking part in another trial where they may receive a serotonergic psychedelic (like psilocybin or LSD) or a placebo. Researchers want to understand how these substances change the brain's inform…
Sponsor: Yale University • Aim: Knowledge-focused
Last updated Jul 11, 2026 00:00 UTC
-
Tafamidis tablet vs capsule: which works better?
Knowledge-focused Stopped earlyThis early-stage study aimed to compare how a tablet form of tafamidis is absorbed in the body compared to the existing capsule form. It involved 24 healthy adults who took a single dose of each form under fed conditions. The study was terminated early, so results may be limited.
Phase 1 • Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Brain and eye clues to emotion recognition in autism and psychosis
Knowledge-focused Stopped earlyThis study aimed to understand why people with autism or schizophrenia sometimes struggle to recognize emotions on faces. Researchers used brain wave recordings (EEG) and eye-tracking to see how participants processed facial expressions. The study included people with autism, sch…
Sponsor: Hôpital le Vinatier • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Scientists probe Brain's consciousness switch during anesthesia
Knowledge-focused Stopped earlyThis study looked at how anesthesia changes brain activity in people with Parkinson's disease or essential tremor who were already scheduled for deep brain stimulation (DBS) surgery. Researchers recorded brain signals during a short period of anesthesia to understand which circui…
Sponsor: University of Texas Southwestern Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Tiny genetic clues may unlock eye disease mysteries
Knowledge-focused Stopped earlyThis study looked at people with cone disorders, a type of inherited eye disease that affects color vision and sharp sight. Researchers analyzed genetic changes of unknown significance to see if they cause disease. The goal was to improve genetic diagnosis, not to test a treatmen…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Peeling eye membrane during retinal surgery: help or hype?
Knowledge-focused Stopped earlyThis study looked at whether peeling a thin membrane inside the eye (the internal limiting membrane) during surgery for a detached retina helps patients see better and prevents scar tissue. The trial was stopped early after enrolling only 21 people, so the results are not strong …
Sponsor: Vienna Institute for Research in Ocular Surgery • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Gut hormone shot aims to strengthen fragile bones in kids with muscle diseases
Knowledge-focused Stopped earlyThis study tested whether two gut hormones, GIP and GLP-2, could reduce bone breakdown in children with spinal muscular atrophy, cerebral palsy, or Duchenne muscular dystrophy who use wheelchairs. Participants received a liquid meal and then either a hormone injection or a placeb…
Sponsor: University of Copenhagen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
New eye camera could spot hidden signs of blindness
Knowledge-focused Stopped earlyThis study tested a new, non-invasive eye imaging method called hyperspectral imaging. It takes pictures of the back of the eye using many different colors of light to find details not visible with standard cameras. About 679 adults with healthy eyes or eye diseases like diabetic…
Sponsor: Center for Eye Research Australia • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
Scientists hunt for clues in rare genetic brain disorder
Knowledge-focused Stopped earlyThis study aimed to observe how MECP2 duplication syndrome progresses over time by measuring biological markers in spinal fluid and blood, and by tracking changes in development, behavior, and seizures. It enrolled 29 males aged 1 month to 65 years with a confirmed genetic diagno…
Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Brain wave test could spot stubborn depression
Knowledge-focused Stopped earlyThis study aimed to find brain and movement markers in people with a type of depression that doesn't respond to standard antidepressants, called anhedonic depression. Researchers measured brain waves (P300), walking speed, and hand movements in 36 participants. The goal was to id…
Sponsor: University Hospital, Rouen • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
Rare disease study aims to map MLIV's natural course
Knowledge-focused Stopped earlyThis study followed 7 people with Mucolipidosis Type IV (MLIV) to learn how the disease naturally progresses. Researchers used tests like neuropsychological exams, blood and urine tests, and brain MRIs to find better ways to measure the disease. The goal was to improve future cli…
Sponsor: Baylor Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:14 UTC
-
Scientists dig into DNA to unravel rare eye disorders
Knowledge-focused Stopped earlyThis study looked at over 100 people with inherited retinal dystrophies, a group of rare eye diseases that can cause vision loss. Researchers collected genetic and eye exam data to find links between specific gene mutations and symptoms. The goal was to better understand these di…
Sponsor: Fondation Ophtalmologique Adolphe de Rothschild • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
New survey aims to better measure life quality in pituitary tumor patients
Knowledge-focused Stopped earlyThis study tested a new questionnaire called Prolac-10 to see if it can accurately measure quality of life in people with prolactinoma (a type of pituitary tumor) who are starting medical treatment. Only 8 people took part before the study was stopped early. The goal was to check…
Sponsor: Ohio State University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:02 UTC
-
Drug interaction study for radiprodil halted early
Knowledge-focused Stopped earlyThis early-stage study looked at how two common drugs (carbamazepine and itraconazole) change the levels of radiprodil in the blood of 30 healthy adults. The goal was to understand safety and dosing for future use in neurological conditions like tuberous sclerosis. However, the s…
Phase 1 • Sponsor: GRIN Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
Rare disease mystery: scientists watch AMN progress in hopes of finding a cure
Knowledge-focused Stopped earlyThis study followed 65 adult men with a rare inherited nerve disease called AMN (a form of spastic paraplegia) to understand how their symptoms change over time. Researchers collected data on walking ability and quality of life. The goal was to fill gaps in knowledge about the di…
Sponsor: SwanBio Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC
-
Hidden heart condition: study seeks to uncover missed diagnosis in heart failure patients
Knowledge-focused Stopped earlyThis study aims to find out how common transthyretin amyloidosis cardiomyopathy (ATTR-CM) is in Russian patients with a certain type of heart failure. Researchers will review medical records and then invite some patients for extra heart tests to confirm or rule out ATTR-CM. The g…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:47 UTC
-
One-Person study aims to unlock FSHD mysteries
Knowledge-focused Stopped earlyThis study looked at one person with facioscapulohumeral muscular dystrophy (FSHD) to better understand the disease. Researchers examined muscle tissue and checked for specific biomarkers. The goal was to learn more about how FSHD affects the body, not to test a treatment.
Sponsor: Nationwide Children's Hospital • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:43 UTC
-
Gene therapy for krabbe disease: did it last?
Knowledge-focused Stopped earlyThis study follows up on children with Krabbe disease who received a one-time gene therapy infusion (FBX-101) in earlier trials. Researchers will monitor safety and measure motor skills over time. Only 2 participants are enrolled, so results are very limited.
Sponsor: Forge Biologics, Inc • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:47 UTC
-
New implant could track seizures for months
Knowledge-focused Stopped earlyThis study tested a small device implanted under the scalp to record brain waves (EEG) continuously for up to 12 weeks in people with epilepsy. The goal was to see if it could detect seizures better than standard short-term hospital monitoring and patient diaries. The trial invol…
Sponsor: UNEEG Medical A/S • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:35 UTC
-
Treadmill training may slow Parkinson's by fighting inflammation
Knowledge-focused Stopped earlyThis study looked at whether intensive treadmill exercise can improve motor symptoms and reduce inflammation in people with early-stage Parkinson's disease. Researchers measured changes in movement scores and blood markers of nerve damage and inflammation in 30 patients who eithe…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:10 UTC